

Journal Pre-proof

Vitamin D and Brain Health: A Systematic Review

Ghinwa M. Barakat, Nour Yassine, Noura B. El Khoury, Nour Ellaboudi, Wiam Ramadan



PII: S2667-2685(26)00022-7

DOI: <https://doi.org/10.1016/j.nutos.2026.100646>

Reference: NUTOS 100646

To appear in: *Clinical Nutrition Open Science*

Received Date: 28 January 2026

Revised Date: 9 March 2026

Accepted Date: 10 March 2026

Please cite this article as: Barakat GM, Yassine N, El Khoury NB, Ellaboudi N, Ramadan W, Vitamin D and Brain Health: A Systematic Review, *Clinical Nutrition Open Science*, <https://doi.org/10.1016/j.nutos.2026.100646>.

This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability. This version will undergo additional copyediting, typesetting and review before it is published in its final form. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Please note that Elsevier's sharing policy for the Published Journal Article applies to this version, see: <https://www.elsevier.com/about/policies-and-standards/sharing#4-published-journal-article>. Please also note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Clinical Nutrition and Metabolism.

Vitamin D and Brain Health: A Systematic Review

Ghinwa M. Barakat¹, Nour Yassine¹, Noura B. El Khoury², Nour EllAboudi¹, and Wiam Ramadan^{1,3*}

¹*Biological and Chemical Sciences Department, School of Arts and Sciences, Lebanese International University, Beirut, Lebanon;*

²*Psychology department, Faculty of Arts and Sciences, University of Balamand, Tripoli, Lebanon;*

³*Nutrition and Food Sciences Department, School of Arts and Sciences, Lebanese International University, Beirut, Lebanon*

*corresponding author: Wiam Ramadan, Lebanese International University, Beirut, Lebanon

E-mail: wiam.ramadan@liu.edu.lb

First Author:

Dr. Ghinwa Barakat and Dr. Nour Yassine

Vitamin D and Brain Health: A Systematic Review

Ghinwa M. Barakat¹, Nour Yassine¹, Noura B. El Khoury², Nour Ellaboudi¹, and Wiam Ramadan^{1,3*}

¹*Biological and Chemical Sciences Department, School of Arts and Sciences, Lebanese International University,*

²*Psychology department, Faculty of Arts and Sciences, University of Balamand, Lebanon*

³*Nutrition and Food Science Department, School of Arts and Sciences, Lebanese International University,*

First Author:

Dr. Ghinwa Barakat and Dr. Nour Yassine

**Correspondence should be addressed to:*

Dr. Wiam Ramadan

Lebanese International University, Beirut, Lebanon

E-mail : wiam.ramadan@liu.edu.lb

Abstract

Vitamin D, once considered solely important for bone health, is increasingly considered a key neuro-steroid involved in brain development and function. This PRISMA-registered systematic review synthesizes evidence on the association between vitamin D status and neuropsychiatric and neurological disorders and evaluates the effects of vitamin D supplementation on brain-related outcomes. It integrates findings from 90 studies including meta-analyses, clinical trials, and observational studies, about the associations between vitamin D status and the range of neuropsychiatric and neurological disorders. From depression, schizophrenia, and autism spectrum disorders to neurodegenerative disorders such as Alzheimer's and Parkinson's, most studies show that low vitamin D is associated with increased risk, increased severity of symptoms, or worse outcomes. Supplementation, particularly for those who are deficient, usually provides improvements resulting in moderate but meaningful improvement in mental health symptoms, neurodevelopmental outcomes, and cognitive function. It is notable and probably most beneficial in individuals with baseline deficiency, and emerging evidence suggests genetic and microbiome factors may impact its benefits. This review emphasizes that vitamin D is a modifiable, low-cost, risk factor for mental and neurological health. This is especially pertinent in vulnerable populations (pregnant individuals; children; aging; psychiatric diagnoses). Vitamin D supplementation cannot be recommended as a primary treatment for neuropsychiatric or neurological disorders, but assessment and correction of deficiency may be considered as part of comprehensive care in

selected high-risk populations. The review protocol was registered in PROSPERO (CRD420261282220).

Keywords: Vitamin D, Brain health, Neuropsychiatric disorders, Depression, Autism, systematic review

1. Introduction

Vitamin D, a fat-soluble ketosteroid hormone, is becoming increasingly acknowledged for its broader physiological functions beyond calcium and phosphate homeostasis. The ample distribution of receptors in the brain and central nervous system suggests the possibility of direct neuro-modulatory effects [1]. Increasingly, vitamin D status is associated with the range of neuropsychiatric diseases; mood disorders, psychosis, developmental disorders and neurodegenerative disorders [2], [3].

Functionally, vitamin D has neurotrophic, antioxidant, and immunomodulatory effects in the brain. It modulates synaptic mechanisms, including neurotransmitter production; in particular serotonin, circadian rhythm and neuroplasticity [4], [5]. The biological mechanisms for vitamin D's role in mental health are plausible and complex. Areas of the brain that regulate emotions and cognition mainly within the limbic system and the prefrontal cortex express both vitamin D receptors and enzymes for local vitamin D activation [6]. Under this context, active vitamin D (calcitriol) may regulate important actions such as inflammation, calcium signaling, and neurotrophic factors, which are used as buffering actions for neuronal survivorship and synaptic activities [7].

In contrast, vitamin D deficiency is characterized by increased susceptibility to oxidative stress and higher levels of inflammatory cytokines; both of which have been causally implicated in depression, anxiety and neurodegeneration [8], [9]. These mechanisms have triggered a wide variety of epidemiological and clinical studies to reveal whether vitamin D insufficiency has a causal mechanistic relationship with any type of psychiatric continuum and whether oral supplementation could be beneficial as an adjunctive therapy [10], [11].

2. Theoretical Framework: Vitamin D's Neurobiological Mechanisms and Pathways

Vitamin D acts as a pleiotropic neuro-steroid with substantial relevance to brain development, structure, and function. The active metabolite, calcitriol (1,25-dihydroxyvitamin D), easily crosses the blood-brain barrier and interacts with vitamin D receptors (VDRs) throughout the central

nervous system, including, but not limited to, the prefrontal cortex, hippocampus, substantia nigra, and hypothalamus [4], [12].

This section integrates the current state of knowledge about the biological mechanisms associated with vitamin D and brain health and provides a conceptual model to framework understanding of vitamin D in neuropsychiatric disorders.

2.1 Core Biological Mechanisms

Vitamin D influences neurobiological processes in genomic and non-genomic ways:

1. **Genomic Regulation:** The vitamin D-VDR complex is a transcription factor that regulates roughly 3% of the human genome [13], [14]. In neural tissue, vitamin D can mediate gene expression responsible for neurotransmitter production [5], [15]; neurotrophic factors[16]; antioxidant processes [17]; and calcium balance [18].
2. **Neuroprotection and Anti-inflammatory Effects:** Vitamin D inhibits pro-inflammatory (IL-6 and TNF- α) cytokines by inhibiting NF- κ B signaling in microglia and astrocytes [19]. Specifically, with neurodegenerative diseases, neuroinflammation promotes disease progression.
3. **Neurodevelopmental Influence:** In sensitive periods of development, vitamin D mediates neuronal differentiation, axonal growth, and synapse which are all critical for proper neurodevelopment [20]. Cortical thickness and white matter development change in animal models prenatally if vitamin D is absent [21].
4. **Gut-Brain Axis Modulation:** Perhaps the most intriguing biological mechanism, vitamin D may influence the gut-brain axis [22]. The gut microbiota has potential significance for overall human health, especially with regard to brain health, and vitamin D has been shown to regulate gut microbiota composition, which relates to the neuroactive metabolites, immune signaling for neuro-inflammation, and other pathways relevant for brain health [23].

2.2 Hypotheses Under Examination

Using this theoretical framework, the systematic review investigates the following hypotheses:

Hypothesis 1: Vitamin D deficiency during critical prenatal and early postnatal developmental windows might have stronger associations with neurodevelopmental disorders (autism spectrum disorder (ASD), Attention-Deficit/Hyperactivity Disorder (ADHD), schizophrenia) than deficiency later in life.

Hypothesis 2: Vitamin D supplementation has therapeutic effects most strongly associated with disorders with prominent neuroinflammatory components (e.g., Multiple Sclerosis (MS), Alzheimer) and among individuals with a deficiency at baseline.

Hypothesis 3: Variants in vitamin D metabolism-related genes (e.g., CYP2R1, GC, VDR polymorphisms) moderate the relationship between vitamin D status and brain health outcomes.

Hypothesis 4: The gut-brain axis is an important pathway through which vitamin D exerts its effects on neuropsychiatric disorders; including ASD and mood disorders.

This theoretical framework provides biological plausibility for vitamin D's involvement in brain health and offers measurable, specific hypotheses to note and interpret literature across diagnostic categories.

3. Objective

The purpose of this systematic literature review is to examine the evidence regarding vitamin D status, which can include both deficiency and supplementation, and a wide range of psychiatric and neurological disorders. The review examines high level evidence; observational studies, randomized control trials (RCTs), and meta-analysis to identify which disorders are linked to low vitamin D and whether treatment to normalize vitamin D levels has measurable clinical effect.

The review discusses various diagnoses such as mood disorders, psychotic disorders, neurodevelopmental disorders, and neurodegenerative disorders and the extent to which vitamin D status impacts health across the lifespan. This review also addresses methodological issues, evidence gaps, and suggests future research priorities to guide clinical and public health action.

4. Methods

4.1 Search Strategy

The search of the literature was systematic and was performed in two databases (PubMed and Google Scholar) to obtain relevant studies in the published period from January 2000 and June 2025 with relevance to our search for research studies examining vitamin D and a range of psychiatric and neurological disorders as outlined in PRISMA [24].

The PubMed search strategy with Medical Subject Headings (MeSH) as the basis of accuracy and coverage and complemented by some relevant keyword variations. The Basic Boolean search strategy was as the following:

```
( "vitamin D"[Mesh] OR "cholecalciferol" OR "25-hydroxyvitamin D" OR "vitamin D deficiency" OR "vitamin D supplementation" )
AND
( "brain"[Mesh] OR "cognition"[Mesh] OR "neurodevelopmental disorders"[Mesh] OR "mental disorders"[Mesh] OR "dementia"[Mesh] OR "depression"[Mesh] OR "schizophrenia"[Mesh] OR "autism spectrum disorder"[Mesh] OR "sleep wake disorders"[Mesh] )
AND
( "supplementation" OR "deficiency" OR "biomarkers" OR "serum levels" OR "RCT" OR "randomized controlled trial" )
```

Filters applied included human studies, English language, and publication date between 2000/01/01 and 2025/06/30, ensuring a focus on recent, clinically relevant evidence.

In parallel, the Google Scholar query was structured to identify high-quality intervention-based evidence by applying domain-specific filters to limit results to established publisher platforms.

The following string was used:

```
( "vitamin D supplementation" ) AND ( autism OR schizophrenia OR depression OR dementia OR ADHD OR "cognitive decline" )
AND ( "RCT" OR "randomized controlled trial" OR "meta-analysis" OR "systematic review" )
site:nature.com OR site:sciencedirect.com OR site:springer.com OR
site:tandfonline.com OR site:wiley.com
```

This strategy is in accordance with recommended practices for systematic reviews looking to balance scope and scientific rigor [25]. Inclusion was restricted to peer-reviewed articles based on

human populations, and articles were prioritized based on being systematic reviews, meta-analyses, or very large cohort or randomized design trials to increase the quality of evidence. The final search date of May 2025 yielded 155 total records (62 from PubMed, 93 from Google Scholar). After de-duplication, 152 unique studies moved on to screening.

4.2 Screening and Selection

Two independent reviewers screened all 152 titles and abstracts against the inclusion criteria we established beforehand. Studies were retained if they examined either Vitamin D status (i.e., serum 25(OH)D levels) or Vitamin D supplementation and resulted in mental or neurological health outcomes.

Studies that examined only non-neurological outcomes (for instance: bone health outcomes) or did not have appropriate mental or neurological outcome measures were excluded. The two reviewers independently cited the selection criteria, with disagreement settled by discussion, following standard systematic review procedures [26].

Following the full-text screening, 90 studies met the established eligibility criteria and were included in the final synthesis. The studies screening process is depicted in **Figure 1**, abiding by PRISMA guidelines.




Figure 1. PRISMA flow diagram depicting the identification, screening, eligibility, and inclusion of studies examining the relationship between vitamin D and brain-related outcomes.

4.3 Data Extraction and Synthesis

Data extraction was performed using a standardized form aimed to include important features of the studies:

- Study design and participant characteristics
- Method of Vitamin D measurement (25(OH)D levels or dose and regimen of supplementation)
- Primary outcomes (e.g., symptom severity, cognitive scores, incidence rates)

- Quantitative outcome information, including effect sizes and statistical significance

Due to the heterogeneity in outcome measures, diagnostic criteria, and intervention procedures meta-analyses were not performed. Data were organized and synthesized qualitatively through a narrative synthesis categorized by diagnostic category (i.e., mood disorders, psychotic disorders, neurodevelopmental disorders). Meta-analyses and large, well-conducted trials were given more weight in the results, following the principles of evidence hierarchies [27].

4.4 Risk-of-Bias Assessment

The methodological rigor and internal validity of the studies that met the inclusion criteria, were evaluated. Risk-of-bias rating was evaluated by two independent reviewers using the Cochrane Collaboration's domain-based tool [28]. For the studies that were RCTs, the following randomized trial domains were used: Random sequence generation (Selection bias); Allocation concealment (Selection bias); Blinding of participants and personnel (Performance bias); Incomplete outcome data (Attrition bias); and Selective Reporting (Reporting bias).

For the observational studies, disciplines with similar five-domain evaluations were used: Control of confounding (significant threat to internal validity); Participant selection (significant threat to internal validity); Outcome measurement (significant threat to internal validity); Handling of missing data (significant threat to internal validity); and Reporting bias (significant threat to validity).

Each domain was rated as low risk, moderate, or high risk. Each study was assigned a risk rating (A = low risk across all domains; B = some concerns; C = high risk) with no numerical weights. Risk ratings are reported and cited in **Supplementary Table S1**, and when discussing study findings, in the results and discussion sections for context.

This review was conducted and reported in accordance with the PRISMA 2020 checklist. Google Scholar was searched as a supplementary source to improve identification of recently published or ahead-of-print randomized controlled trials not yet indexed in major databases. Study quality was assessed using an A/B/C grading system to enable uniform evaluation across heterogeneous study designs; the GRADE framework was not applied due to the review's broad scope and inclusion of diverse observational and mechanistic evidence, for which GRADE is less suitable.

5. Results

5.1 Overview of Included Studies

In total, 90 publications were included, comprising systematic reviews and meta-analyses ($n \approx 30$), narrative reviews ($n \approx 20$), and original research studies ($n \approx 40$) that met our criteria. The complete dataset, including study design, sample size, intervention/exposure, outcome, size, and risk-of-bias grade for each included record, is presented in Supplementary Table S1. Most publications were recent (2018–2025), reflecting the growing scientific interest in vitamin D and brain health. Representative high-quality studies are summarized in **Table 1**. Risk-of-bias grades (A=low/high quality; B=moderate/unclear; C=high/narrative; full criteria in Methods) are summarized below and detailed in Supplementary Table S1.

Studies spanned conditions with varying evidence strength per Categories of Evidence: Category A (strongest: neurodevelopmental, e.g., ASD meta-analyses); Category B (moderate: mood disorders, e.g., depression meta-analysis); Category C (emerging: neurodegeneration, e.g., narrative review). Most publications from 2018 to 2025 demonstrate increasing research interest in this area. High-quality studies—prioritizing A- and B-grade evidence, including meta-analyses and large randomized controlled trials (RCTs)—are presented in Table 1, with explicit risk-of-bias assessments and evidence category labels.

Evidence from RCTs provided insights into causality and dose–response effects. **Table 2** summarizes five representative trials across ASD, depression, restless legs syndrome (RLS), ADHD, and Parkinson’s disease. In ASD, an open-label study administering vitamin D at $300 \text{ IU} \cdot \text{kg}^{-1} \cdot \text{day}^{-1}$ (maximum 5,000 IU/day) in combination with calcium for 16 weeks to children with marked vitamin D deficiency (baseline $25(\text{OH})\text{D} \sim 15 \text{ ng/mL}$) reported a significant within-group improvement on the Childhood Autism Rating Scale (mean change -4.52 ; $p < 0.001$), although the lack of a control group limits causal inference [29].

Table 1: Representative studies overview. Snapshot of high-quality meta-analyses, reviews and original studies that form the evidential backbone for each condition assessed.

Study	Condition	Study Design	Sample Size	Effect Summary	Risk of Bias	Category of evidence
[11]	Depression	Meta-analysis	~24,510	SMD ~ -0.4; Moderate reduction in depression symptoms	Low	B
[30]	Autism	Meta-analysis	~1,652	Children with ASD had ~7.4 ng/mL lower 25(OH)D	Low	A
[31]	ASD/ADHD	Dose-response Meta-analysis	~3,720	Every 10 ng/mL ↑ in 25(OH)D → ~19% ↓ ASD risk	Moderate	A
[32]	Perinatal Depression	Systematic Review	~25 studies	~4.6 ng/mL lower 25(OH)D in depressed pregnant women	Low	B
[33]	Neurodegeneration	Review	N/A	Vitamin D slows decline via neuroprotective, anti-amyloid effects	Narrative	C

Abbreviations: SMD = Standardized Mean Difference; ASD: Autism Spectrum Disorder

Table 2. Randomized Controlled Trials of Vitamin D Supplementation in Neurological Disorders

Study (Year)	Condition	Dose / Regimen	Duration	Baseline 25(OH)D (ng/mL)	Outcome Measure	Effect Size	p-value	Interpretation	Risk of bias	Evidence category
Feng et al., 2017	Autism	300 IU·kg ⁻¹ ·day ⁻¹ (max 5,000 IU) + Ca	16 wk	~15	CARS	Mean change -4.52	<0.001	Significant within-group improvement (open-label, n=37)	A	A
Wali et al., 2019	Restless Legs Syndrome	50,000 IU/week	12 wk	12.8 ± 4.2	IRLS	Mean change -3.8	0.03	Significant within-group (open-label, n=18)	B	B
Hemamy et al., 2021	ADHD (+Mg)	50,000 IU/week + 6 mg·kg ⁻¹ ·day ⁻¹	8 wk	Not reported	SDQ (total difficulties)	Mean diff - 2.98	0.002	Significant improvement (RCT, n=66)	A (RCT)	A
Suzuki et al., 2013	Parkinson's Disease	1,200 IU/day	12 mo	21.8 ± 8.3	Hoehn & Yahr	+0.02 vs +0.33	0.005	Stabilized progression (RCT, n=114)	A (RCT)	B

Abbreviations: CARS = Childhood Autism Rating Scale; GDS = Geriatric Depression Scale; IRLS = International Restless Legs Scale; ADHD-RS = ADHD Rating Scale; UPDRS II = Unified Parkinson's Disease Rating Scale (Activities of Daily Living); SMD = Standardized Mean Difference; MD = Mean Difference; n.s. = non-significant.

A forest plot of these trials (**Figure 2**) shows that four of five RCTs favored vitamin D, with the most precise estimates in autism [29]. The restless legs trial displayed the widest confidence interval, highlighting heterogeneity in precision and underscoring the need for larger, condition-specific RCTs.




Figure 2. Forest plot of vitamin D supplementation effects across five clinical trials (illustrative; non-pooled). Circles indicate point estimates (mean difference or standardized mean difference), and horizontal lines represent 95% confidence intervals. The dashed vertical line denotes no effect (0); negative values favor vitamin D supplementation. Two studies were open-label (Feng et al., 2017; Wali et al., 2019) and two were RCT (Hemamy et al., 2021; Suzuki et al., 2013). ADHD (+magnesium) and Parkinson's disease demonstrated statistically significant effects favoring supplementation. The restless legs syndrome trial showed a nominal benefit but with wide confidence intervals, reflecting substantial uncertainty due to small sample size. Confidence intervals were approximated from reported p-values because CIs or standard deviations were not provided in Table 2; effects were not pooled due to heterogeneity of outcomes.

5.2 Depression and Mood Disorders

5.2.1 General Depression

A substantial body of evidence supports a link between low vitamin D status and depression. Meta-analyses of observational studies consistently show that individuals with vitamin D deficiency have higher odds of depression compared to those with sufficient levels. For example, a study reported that people with lower serum 25(OH)D had approximately 1.85-fold increased odds of depression [34]. Longitudinal data strengthen the causal argument: prospective cohorts demonstrate that vitamin D deficiency often precedes the development of depressive symptoms [35]. On the interventional side, RCTs present mixed but overall encouraging findings. The umbrella meta-analysis by Musazadeh et al. (2023), pooling 10 meta-analyses of RCTs, concluded that vitamin D supplementation is associated with moderate reduction in depressive symptoms (pooled SMD ≈ -0.40 vs. placebo) [11]. The antidepressant effect of vitamin D supplementation appears most pronounced among individuals with baseline deficiency (<20 ng/mL) or those with major depressive disorder. This aligns with mechanistic data suggesting that vitamin D exerts neurotrophic and anti-inflammatory actions (e.g., via NLRP3 inflammasome suppression) that are particularly beneficial in states of deficiency [36].

Similarly, a systematic review of antenatal depression (Centeno et al., 2024; ~ 25 studies) found that depressed pregnant women had mean serum 25(OH)D levels approximately 4.6 ng/mL lower than non-depressed women, with low risk of bias [32].

In contrast, a randomized controlled trial in older adults with depression and low baseline vitamin D levels (18.3 ± 6.5 ng/mL) found no significant benefit of vitamin D supplementation at 2,000 IU/day over 12 months on depressive symptoms measured by the Geriatric Depression Scale ($p = 0.41$) [37]. For RLS, weekly high-dose supplementation (50,000 IU/week; baseline 42.6 ± 31.1 nmol/L) for 12 weeks produced a non-significant reduction in symptom severity [38]. In ADHD children, an 8-week randomized, double-blind, placebo-controlled trial showed that 66 participants receiving weekly high-dose vitamin D (50,000 IU) plus daily magnesium (6 mg/kg/day) or placebo experienced significant improvements in multiple strengths and difficulties questionnaire (SDQ) domains (emotional, conduct, peer problems, prosocial, total difficulties, externalizing, and internalizing scores; all $p \leq 0.007$) versus placebo [39]. In Parkinson's disease (baseline 25(OH)D ~ 22 ng/mL), 1,200 IU/day vitamin D3 supplementation for 12 months stabilized Hoehn & Yahr

stage versus placebo worsening (+0.02 vs. +0.33; $p=0.005$), notably in VDR FokI TT/CT genotypes [40].

In a recent randomized controlled trial (RCT) examining adjunctive vitamin D supplementation in patients with major depressive disorder (MDD), using diffusion tensor imaging and resting-state functional MRI, clinical symptom scores did not show significant differences between the vitamin D and placebo groups. However, the placebo group exhibited progressive declines in white matter integrity and functional connectivity, changes that were not observed in the vitamin D group. These findings suggest a potential neuroprotective role of vitamin D in maintaining brain network integrity, even in the absence of clear symptomatic improvement[41].

Additional neuroimaging evidence also suggests possible sex-specific effects. A study investigating vitamin D status in MDD reported that female patients with vitamin D deficiency exhibited disruptions in frontal brain connectivity and cognitive decline compared with controls. Specifically, female MDD patients showed reduced functional connectivity density and network-specific connectivity in the left middle frontal gyrus, whereas such alterations were not observed in males. These findings point to potential sex-specific neuroprotective benefits of vitamin D repletion, although prospective clinical trials are needed to confirm this association [42].

5.2.3 Seasonal Affective Disorder (SAD) and Other Mood Conditions

Vitamin D has an intuitive link to seasonal mood regulation, as endogenous synthesis declines in winter when SAD incidence peaks. Observational studies indicate that individuals with SAD tend to have lower wintertime 25(OH)D levels [43] (grade B). Small trials suggest that supplementation can improve late-winter mood compared to placebo, although findings remain inconsistent [44]. Current evidence does not justify recommending vitamin D as a primary therapy for SAD, but it supports correcting deficiency as part of overall management (category C).

In bipolar disorder, research is preliminary but indicates that vitamin D insufficiency is prevalent and may be more strongly associated with depressive rather than manic phases [45] (grade C). Another area of interest is suicidality: lower serum 25(OH)D levels have been reported in individuals with suicidal ideation, and a recent review proposed that vitamin D could reduce suicide risk by ameliorating neuroinflammation [46]. While causal inference remains speculative,

(Category C), maintaining adequate vitamin D is increasingly recognized as part of a holistic approach to mood disorder care.

Clinical evidence aligns with these pathways: the strongest evidence supports vitamin D's role in depression (RCTs, meta-analyses), followed by anxiety disorders (cross-sectional, small RCTs). Emerging but less conclusive data suggest relevance in seasonal affective disorder, bipolar disorder, and suicidality A/B grades), (**Figure 3**).




Figure 3. Proposed mechanistic pathways linking vitamin D to neuropsychiatric outcomes. Vitamin D (25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)₂D]) influences serotonin synthesis, neurotrophic factor signaling (BDNF, NGF), inflammatory cytokine balance, and hypothalamic–pituitary–adrenal (HPA) axis regulation. These mechanisms are associated with a spectrum of clinical outcomes, with strongest evidence for depression and more limited or emerging evidence for anxiety, seasonal affective disorder, bipolar disorder, and suicidality.

5.2.2 Anxiety disorders

Fewer studies have examined anxiety specifically, but the available literature parallels findings in depression. A comprehensive review by Akpınar & Karadağ (2022) highlighted that vitamin D deficiency frequently co-occurs with anxiety symptoms, often overlapping with depression. Biological plausibility exists, given vitamin D's antioxidant, anti-inflammatory, and HPA-axis modulatory roles, all implicated in anxiety pathophysiology [47] (grade B).

Cross-sectional and observational studies report lower vitamin D levels in individuals with elevated anxiety symptoms and, in some clinical samples, diagnosed anxiety disorders compared with controls [48]. Intervention evidence remains limited; however, small RCTs and meta-analyses suggest potential benefits of vitamin D supplementation on anxiety and related mood outcomes in specific populations. For example, adjunctive vitamin D supplementation has been associated with reductions in anxiety and negative emotional outcomes in certain clinical populations, including older adults with prediabetes and patients with fibromyalgia [48], [49], [50] (grade B).

Definitive evidence from large, anxiety-focused randomized controlled trials is lacking. Given its low risk profile and consistent observational associations with anxiety symptomatology, vitamin D repletion may be considered a supportive intervention in anxiety management, complementing standard therapies rather than serving as a standalone treatment.

5.3 Perinatal Mental Health

Vitamin D status during pregnancy and postpartum has attracted increasing attention because deficiency is common and may influence maternal mood regulation. Pregnancy involves heightened metabolic demand, and vitamin D is implicated in HPA-axis modulation, serotonergic pathways, and neuroimmune balance, all relevant to mood disorders.

5.3.1 Antepartum (Antenatal) Depression

A systematic review and meta-analysis by Centeno et al. (2024) integrated 25 observational studies and reported that pregnant women with antenatal depression had significantly lower 25(OH)D concentrations than non-depressed women, averaging 4.6 ng/mL lower levels (95% CI -8.9 to -0.4 ng/mL) [32]. Similarly, Yuan et al. (2024) confirmed lower vitamin D levels among prenatally depressed women (SMD -0.41, 95% CI -0.57 to -0.25) (grade B). These associations persisted

after adjusting for common confounders, although overall evidence quality was rated low [51] (Category B).

Longitudinal studies suggest temporality: Evanchuk et al. (2024) (grade B) found baseline vitamin D adequacy during mid-pregnancy predicted lower risk of subsequent depressive symptoms [52]. Mechanistically, vitamin D may influence mood. Interventional evidence is limited but promising. A randomized controlled trial by Vaziri et al. (2016) (grade B) demonstrated that daily vitamin D supplementation (2,000 IU/day) initiated in late pregnancy reduced depressive symptom scores compared with placebo [53] (Category B). These findings, though requiring replication in larger samples, suggest that antenatal repletion may confer mood benefits, particularly in deficient women.

5.3.2 Postpartum Depression (PPD)

The postpartum period is another vulnerable time for mood disturbances. Observational evidence consistently shows lower maternal vitamin D levels among women with PPD. Yuan in 2024 reported that women with postpartum depression had serum 25(OH)D concentrations significantly lower than healthy postpartum women (SMD = -1.62, 95% CI -2.62 to -0.62, approximately 10 nmol/L or ~4 ng/mL lower) [51]. Case-control studies such as Abedi et al. (2018) (grade B) found that women with 25(OH)D <20 ng/mL had a 3–4 fold increased risk of PPD (OR 3.30) [54].

A small RCT by Amini et al. (2022) (grade C) found that combined vitamin D and calcium supplementation during pregnancy reduced postpartum depression scores [55]. Another systematic review by Gould et al. (2022) (grade B) found small RCTs suggesting vitamin D supplementation in the perinatal period reduced depressive symptoms versus placebo, though sample sizes limit conclusions [56]. These align with larger meta-analyses like Musazadeh et al. (2023), which showed higher doses significantly reduce symptoms, particularly in deficient individuals; risk of bias is grade A (supplementary data) [11].

Overall, perinatal vitamin D deficiency is consistently linked with higher risk of antenatal and postpartum depression, with pooled data suggesting a measurable effect size. Evidence for anxiety outcomes remains sparse and inconsistent, indicating that vitamin D's influence may be stronger on depressive pathways than on anxiety during the perinatal period (Category B/C). Clinical practice increasingly acknowledges these findings. Some guidelines now recommend considering

vitamin D screening and correction in pregnant women with a history of mood disorders, as part of multifactorial prevention strategies that also include psychosocial and psychiatric care.

Figure 4 summarizes the proposed biological pathways linking vitamin D to perinatal mental health outcomes. Vitamin D may influence mood through effects on serotonin synthesis, regulation of the hypothalamic–pituitary–adrenal (HPA) axis, neuroimmune and anti-inflammatory cytokine balance, and neuroplasticity and trophic support. These mechanisms are most consistently associated with antenatal depression, where observational studies and meta-analyses show concordant findings and small RCTs suggest benefits among deficient women. Evidence for postpartum depression is moderate, with lower maternal 25(OH)D levels associated with higher PPD risk and limited RCT support for supplementation, while associations with perinatal anxiety remain inconsistent and require dedicated trials.




Figure 4 Mechanistic and clinical links between vitamin D and perinatal mental health. Vitamin D influences perinatal mood through multiple pathways including serotonin synthesis (TPH2), HPA-axis modulation, neuroimmune balance, and neuroplasticity. On the clinical side,

strongest evidence exists for antenatal depression (consistent observational data, meta-analyses, small RCTs), moderate evidence for postpartum depression, and limited evidence for perinatal anxiety, highlighting the need for targeted trials.

5.4 Schizophrenia and Other Psychotic Disorders

5.4.1 Vitamin D and Schizophrenia Risk

The link between early life vitamin D status and schizophrenia risk has been confirmed by large neonatal dried-blood-spot studies. In Denmark, Eyles et al. (2018) correlated neonatal 25(OH)D and found infants at the lowest quintile levels were at a significantly greater risk of developing schizophrenia in adulthood ($\approx 40\text{--}50\%$ risk increase) compared to the highest quintile [57]. McGrath et al. (2010) noted a U-shaped relationship between neonatal vitamin D and later schizophrenia with low (and likewise high) concentrations serving as risk-promoting [58]. Recent registry-based evidence incorporating vitamin D-associated biomarkers and genetics further supports the neonatal signal across various disorders including schizophrenia [59]. Collectively, this is in accordance with a developmental role for vitamin D and brain pathways relevant for psychosis.

Maternal vitamin D during pregnancy has been considered as a prenatal determinant, with some recent reviews demonstrating some evidence for vitamin D in fetal brain development [60]; however, one large national cohort study, reported no correlation with early-pregnancy 25(OH)D and offspring schizophrenia [61]. Interestingly, while neonatal deficiency consistently indicates elevated risk, maternal levels varied by timing, assay, and design, emphasizing the need for gestational-window-specific work up.

The developmental vitamin D literature has focused mechanistically on associations with dopaminergic maturation, cortical circuit development, and immune/inflammatory tone — biological systems reasonably hypothesized to relate to schizophrenia pathophysiology [1], [58]. Taken together, these studies collectively support a developmental role for vitamin D in schizophrenia, highlighting consistent neonatal effects and more variable maternal influences.

5.4.2 Vitamin D Status in Schizophrenia Patients

Regardless of developmental risk, low 25(OH)D is prevalent in schizophrenia. Results from several meta-analyses and large observational syntheses demonstrate lower average levels in patient groups vs. controls, and high prevalence of insufficiency and deficiency (often > 50%). For example, Valipour and colleagues found that vitamin-D deficient individuals were approximately 2.1 times more likely to have schizophrenia [62]; redone analyses [63] report mean differences of approximately 4-5 ng/mL lower in cases. Contemporary cohorts still show prevalence deficiency including antipsychotic naive or early course groups. Within schizophrenia samples, several studies have found relations of lower vitamin D to poorer symptom domains or cognition, though results have been mixed [64].

5.4.3 Supplementation Trials in Schizophrenia

The randomized trials have been modest in number and results unclear. Krivoy et. al (2017) examined chronic clozapine-treated patients with low serum vitamin D levels and found no change in psychotic symptoms, but a trend to improvement in cognitive or performance measures [65]. In the first-episode/early psychosis cohort of the multicenter DFEND RCT, vitamin D treatment was not associated with significant benefit on the PANSS at 3-6 months, including in those with baseline deficiency [66]. Combinations are being explored: an RCT in 2024 showed vitamin D plus probiotics resulted in significant improvement in cognition and cognitive performance in schizophrenia core measures [67] demonstrating additive helps further substantiate but not only singular antipsychotic. In summary, supplementation appears safe, disappointing symptoms outcomes, but potentially cognitive measurable differences or notables in fragmented patients; more investigation needed [65].

5.5 Neurodevelopmental Disorders

5.5.1 Autism Spectrum Disorder

Vitamin D and Autism Risk:

The potential of vitamin D to support fetal brain development and early life neural health [31] has also led to the research of the potential of vitamin D in relation to autism spectrum disorder (ASD). An unequivocal finding from studies of children with autism is that they have lower vitamin D levels than their typically developing peers [68]. Wang et al. (2020) performed a systematic review

and meta-analysis in 2020 of 24 case–control studies which found that children and adolescents with ASD had significantly lower mean serum 25(OH)D concentrations—approximately 8–10 ng/mL lower—than age-matched controls [30]. Additionally, vitamin D deficiency (often defined as serum levels of 20 ng/mL) is present more often in ASD groups. Although case–control studies cannot infer causation, the patterns and consistency of associations across countries and racial groups which may have different baseline vitamin D levels are notable [69].

Vitamin D levels in pregnancy

Multiple studies have assessed vitamin D status early in life (maternal pregnancy levels or neonatal blood levels) and followed-up with autism diagnoses [70]. Results have been mixed but show overall that low early life vitamin D is associated with increased risk for ASD.

Wang et al. (2020; ~ A total of 1,652 participants) demonstrated that children with ASD had serum 25(OH)D concentrations approximately 7.4 ng/mL lower than controls [30].

A meta-analysis of prospective studies found that children had a ~54% increased risk for disorder later in life with lower prenatal or neonatal vitamin D levels. For instance, pregnant women with deficient 25(OH)D mid-gestation from a Dutch cohort sample were over two times as likely to have an autistic child than women with sufficient levels [71]. In another cohort study with Chinese neonates with very low vitamin D levels it was found that they had increased odds of receiving an ASD diagnosis in childhood. A dose-response meta-analysis conducted by Tirani et al. (2023) found each 10 ng/mL increase in maternal 25(OH)D was associated with 19% decrease of child ASD diagnosis rates. They found that women with vitamin D in the highest maternal vitamin D category had an estimated 43% lower odds of having a child diagnosed with ASD than women in lowest maternal vitamin D category [31].

A dose–response meta-analysis by Tirani et al. (2023; ~2,671 participants) further indicated that each 10 ng/mL increase in maternal vitamin D was associated with a 19% lower risk of autism spectrum disorder in offspring, with an overall moderate risk of bias [31].

Not every study found an effect, a Swedish study found a weak neonatal association and no maternal association [72]. Overall, pooled evidence suggest in the contrary: i.e. higher maternal vitamin D correlated with lower odds of child receiving an ASD diagnosis[73], [74]. A dose-

response meta-analysis conducted by Tirani et al. (2023) found each 10 ng/mL increase in maternal 25(OH)D was associated with 19% decrease of child ASD diagnosis rates. They found that women with vitamin D in the highest maternal vitamin D category had an estimated 43% lower odds of having a child diagnosed with ASD than women in lowest maternal vitamin D category [31]. Taking results together suggest one protective mechanism of adequate maternal vitamin D in neurodevelopment. Possible mechanisms to explain the link between vitamin D and ASD include vitamin D's potential role in differentiating brain cells to modulate neurotransmitter levels and modulation of immune activation during pregnancy, alone or in combination may have a role in autism pathogenesis.

Vitamin D supplementation in ASD

The most intriguing area is emerging evidence that vitamin D supplementation may positively impact core symptoms of ASD in diagnosed children [75]. Multiple randomized controlled trials (RCTs) in the last 10 years have evaluated high-dose vitamin D3 in young children with autism. A 2020 meta-analysis of double-blind RCT studies (with an N of greater than 200) found that vitamin D supplementation significantly improves ASD symptoms, especially social interaction impairments and stereotyped behaviors, shown by national standardized scales. Children receiving vitamin D showed lower scores on the Childhood Autism Rating Scale and improved social responsiveness compared to a placebo group [75]. On a practical level, a number of parents and clinicians saw improvements in eye contact, socialization, and communication occurring after 2-3 months after a vitamin D trial (at doses of generally 2000–5000 IU/day), especially if children were low in vitamin D level [76]. Another systematic review in 2022 reconfirmed vitamin D is a safe and possible effective adjunct for ASD treatments, but it stressed that an optimal dose and long-term effects need further study [69]. A systematic review of vitamin D in combination with additional nutrients was also evaluated: for example, combining vitamin D with omega-3 fatty acids supplementation showed greater improvement in social affect in an open-label study [77]. These findings and evidence justify that vitamin D supplementation is rising in popularity among parent and caregiver of children with autism. Vitamin D is low-cost and has a very positive safety profile therefore some recommend vitamin D supplementation for children with ASD who are low in Vitamin D, as benefits are at least it can make improvements with core symptoms or concurrent

issues (ex: sleep and attention) symptoms [78]. But it needs to be substantially noted, vitamin D is not a cure for autism, nor do all children benefit. This seems to mainly benefit children with low vitamin D or related biomarkers at baseline (e.g. high inflammation) [79].

In conclusion, vitamin D holds a significant role in autism spectrum disorder. Adequate vitamin D while pregnant may decrease autism risk in offspring, while for diagnosed children, restoring vitamin D deficiency may improve symptoms. Overall, this information also reminds us of the importance of nutritional screening and trials in pregnancy and early childhood. This also raises research possibilities: waiting for results of trials looking to see if treating vitamin D deficiency in pregnancy prevents Autism; and whether sustained higher Vitamin D doses in children with Autism produces larger or longer-lasting outcomes. For now, ensuring adequate vitamin D levels is valuable in providing recommended practice in ASD standards of care.

5.5.2 Attention-Deficit/Hyperactivity Disorder (ADHD)

Levels of Vitamin D during pregnancy

There are some shared nutritional risk factors of attention-deficit/hyperactivity disorder that overlap with those of autism. Research on the association of vitamin D and ADHD is relatively new, but emerging studies have reported vitamin D inferred deficiency might disturb attentive and behavioral function in pediatric populations [79]. Mothers' vitamin D status may affect children's ADHD risk just as in autism [80]. A 2023 dose–response meta-analysis established a significant inverse relationship between maternal vitamin D levels and the ADHD risk in the offspring [31]. More specifically, mothers with higher 25(OH)D levels had children who were at lower odds of receiving an ADHD diagnosis; highest and lowest maternal vitamin D levels resulted in an approximate 35% increase in the odds of the child having ADHD [81]. Furthermore, for every 10 ng/mL of increased maternal vitamin D, child risk of ADHD was predicted to decrease ~18% [31]. These results were consistent with large independent studies such as Finnish cohort which noted low prenatal vitamin D exposure was associated with a significantly higher risk of ADHD in the child (e.g., Odds Ratio of approximately 1.3–1.5 for deficiency) [82]. The biological rationale is that vitamin D is involved in early brain development, including dopaminergic systems associated with ADHD pathology. Overall, sufficient vitamin D in pregnancy may provide a protective factor

against ADHD and further highlights the importance of nutrition in pregnancy for neurodevelopment.

Vitamin D Levels in Children with ADHD: On the other hand, the literature on children with ADHD has indicated that these peer children with ADHD have lower vitamin D levels compared to children without ADHD in multitudes of cohorts. For instance in Turkey, China, and the USA, children with ADHD had higher frequency of vitamin D deficiency and levels of vitamin D which were several ng/mL levels below their control children without ADHD [83], [84]. Low serum 25(OH)D in these children statistically correlated with more severe ADHD symptoms and poorer performance on cognitive tests that assess attention and impulse control. One potential rationale could be vitamin D deficiency may be enhancing the severity of ADHD symptoms by affecting executive function or effects through neurotransmitters since vitamin D can affect catecholamine and neurotrophic factor levels in the brain. However, these associations could also be confounded (i.e., kids with ADHD play less outside/in nature or diet effects) and therefore conclusions should be made cautiously [3].

Vitamin D supplementation in ADHD

Clinical trials and other pilot studies have evaluated the addition of vitamin D supplementation compared to their current ADHD approaches, and some have had promising results. Pinto et al. (2022) reviewed dietary interventions in ADHD and summed up that only vitamin D (sometimes with magnesium) has been shown to reduce ADHD symptoms as a nutritional supplement, and only in vitamin D deficient children [85]. The review reported that vitamin D would reduce ADHD symptoms in patients with low 25(OH)D levels, better attention, and some trials did show that some aspect of hyperactivity was reduced. For example, one RCT implemented high-dose vitamin D (2000 IU once daily for 8 weeks) in vitamin D deficient children with ADHD, and reported substantial improvement in cognitive attention scores, and less hyperactive/impulsive behavior compared to placebo [86]. Another small trial utilized vitamin D with magnesium, and noted additional benefits to behavioral regulation [39]. Readers should be cautioned that benefits were not observed in children who had baseline vitamin D levels that were sufficient for adequate health; therefore, therapeutic benefits require correcting a nutritional deficiency that was aggravating ADHD symptoms. This aligns with neuroimaging studies suggesting that vitamin D may affect

parts of the brain involved in ADHD (i.e. pre-frontal cortex [87]). Although the evidence is still sparse, it appears that vitamin D may serve as a valued adjunct in a multi-modal approach for pediatric cases of ADHD, particularly for children who are deficient in vitamin D or if they take a poor diet or expose to sunlight. Possible sufficient vitamin D across the span of treatment with behavioral therapies, medications, or both, may ameliorate the overall brain function as it relates to ADHD symptoms.

In addition to ADHD, vitamin D may also influence ADHD-related behaviors (attention span, impulsivity, etc.) in general youth populations [88]. Some population studies linked higher vitamin D during childhood to improved academic performance, less behavioral problems, but causation was hard to prove [89], [90]. Notably, a study on “screen time” indicated children with excessive “screen time” exposure (potentially limited outdoor or sun exposure) had lower vitamin D levels and greater level of ADHD-like behaviors. This suggests a link between lifestyle, vitamin D, and ADHD-like behaviors [91]

In conclusion, having adequate vitamin D levels throughout pregnancy and childhood may reduce the prevalence and severity of ADHD. Public health strategies such as maternal supplementation for their children cultivated that may result in positive neurodevelopment outcomes. Practically, checking vitamin D levels for children with ADHD who are difficult to manage with and possibly supplementing to ensure weight appropriate vitamin D levels if were low would be suggested based on the abundance well documented evidence.

5.6 Neurodegenerative and Autoimmune Disorders

Vitamin D’s immunomodulatory and neuroprotective roles have placed it at the center of research into neurodegenerative and autoimmune disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS) [33], [92]. These conditions share mechanisms of chronic inflammation, protein aggregation, oxidative stress, and calcium toxicity, all of which vitamin D may influence through genomic and non-genomic actions [33], [93].

5.6.1 Cognitive Decline and Alzheimer's Disease (AD)

Low vitamin D status has consistently been associated with cognitive impairment in older adults. Prospective cohorts show that individuals with low level of 25(OH)D have faster declines in memory and executive function and a higher risk of dementia [94]. Meta-analyses confirm that vitamin D deficient older adults are at significantly higher risk of incident AD [95]. *Pathophysiologically, vitamin D regulates amyloid- β metabolism and may also modulate tau pathology by attenuating tau hyperphosphorylation by enhancing phagocytic clearance and reducing plaque accumulation. It also reduces oxidative stress and supports neuronal survival via antioxidant pathways [96].* In a systematic review (Fu et al., 2024), vitamin D supplementation was found among some trials in mild cognitive impairment (MCI) to be possibly associated with stabilization or modest improvement in cognitive function, especially in domains such as memory or global cognition; however, specific effects on attention and orientation were less consistently reported [97]. Large prevention trials such as VITAL-COGNITION by Vyas et al. in 2023 did not find benefits in the general elderly population, though subgroup analyses suggested possible effects in those with baseline deficiency. Current consensus: vitamin D repletion is advisable in AD and MCI, but it cannot yet be recommended as a disease-modifying therapy [98].

5.6.2 Parkinson's Disease (PD)

Vitamin D deficiency is common in PD and correlates with worse motor severity and postural instability. A meta-analysis confirmed that PD patients are significantly more likely to be vitamin D deficient compared with controls [99]. Prospective studies show that higher baseline vitamin D predicts lower PD incidence, supporting a potential protective role [100]. Mechanistically, vitamin D protects dopaminergic neurons against oxidative damage and neuroinflammation in the substantia nigra. A RCT demonstrated that vitamin D supplementation (12,00 IU/day for 12 months) slowed motor decline in non-carriers of VDR risk polymorphisms [40]. Another pilot RCT reported improvements in mood and wellbeing with supplementation [17]. These findings highlight both potential benefits and the role of genetic modifiers (e.g., VDR polymorphisms) in therapeutic response.

5.6.3 Multiple Sclerosis (MS)

MS is a prototypical autoimmune neuroinflammatory disease where vitamin D is a recognized environmental risk factor. Populations at higher latitudes (low UV exposure) have greater MS incidence, and low serum 25(OH)D is consistently linked with higher risk and relapse activity [101]. A systematic review by Głąbska et al. (2021) reported that supplementation improved mood and quality of life in MS patients. Interventional studies suggest that high-dose vitamin D can reduce relapse rates and MRI lesion activity while also alleviating comorbid depression and fatigue [102], [103]. Immunologically, vitamin D shifts T-cell responses from a pro-inflammatory (Th1/Th17) toward a tolerogenic (Treg, Th2) profile, reducing autoimmunity [104].

5.6.4 Amyotrophic Lateral Sclerosis (ALS)

Evidence for ALS remains preliminary but notable. ALS patients with higher serum 25(OH)D show slower functional decline and better cognitive preservation [105]. A retrospective study suggested that supplementation was linked to longer survival by several months [33]. Mechanistically, vitamin D may support motor neuron survival and muscle metabolism, though causality is not established. Clinical guidelines for ALS do not currently endorse supplementation for disease modification, but screening and correction of deficiency are advisable, especially given the high prevalence of immobility and sun-exposure limitations in these patients. Across neurodegenerative and autoimmune disorders, vitamin D insufficiency is highly prevalent and frequently linked to worse outcomes.

While causal proof is strongest in MS (risk and relapse activity), evidence for AD, PD, and ALS remains mixed but biologically plausible. Vitamin D is unlikely to act as a cure but represents a low-cost adjunctive intervention that supports neurological health and general wellbeing. Ongoing large RCTs will be critical to define its role in disease progression.

5.7 Sleep Disorders

Beyond psychiatric and neurological disorders, vitamin D has been increasingly studied in relation to sleep disorders, particularly obstructive sleep apnea (OSA), restless legs syndrome (RLS), and insomnia/sleep quality (**Figure 5**). Sleep health has profound implications for mental well-being, and vitamin D's roles in neuromuscular function, dopamine synthesis, and circadian regulation provide biological plausibility for these associations.

5.7.1 Obstructive Sleep Apnea (OSA)

OSA is characterized by recurrent upper airway obstruction during sleep, strongly associated with obesity but also influenced by neuromuscular and inflammatory pathways [106]. Meta-analyses consistently report lower 25(OH)D in OSA patients versus controls. Li et al. (2020) demonstrated that vitamin D deficiency is significantly more prevalent in OSA, with an inverse correlation between serum vitamin D and apnea–hypopnea index (AHI) severity [83]. More recently, a systematic review by Serafin et al. (2025) confirmed these findings, showing that vitamin D deficiency correlates with greater OSA severity even after adjusting for BMI, indicating an effect beyond obesity [107]. In a systematic review, it has found that in vitamin-D-deficient patients with obstructive sleep apnea (OSA), vitamin D supplementation has been reported to improve sleep-quality scores and reduce daytime fatigue, effects that may be mediated in part by reductions in pro-inflammatory cytokines [108]. Observational work also suggests that correcting deficiency in OSA patients may improve comorbid depressive symptoms [109]. While vitamin D cannot substitute for standard OSA management (CPAP, weight reduction), sufficiency may support sleep quality and mood in OSA patients.

5.7.2 Restless Legs Syndrome (RLS)

RLS is a sensorimotor disorder marked by unpleasant leg sensations, urge to move, and sleep disruption. Multiple studies demonstrate lower mean vitamin D in RLS patients. A meta-analysis by Xu et al. (2025) reviewed vitamin-related interventions and concluded that vitamin D deficiency is associated with higher RLS risk and severity, and supplementation reduces symptom severity in deficient patients. It was reported that vitamin D supplementation significantly improved RLS severity scores and sleep satisfaction in vitamin D-deficient individuals [38], [110]. Mechanistically, vitamin D's role in dopaminergic pathways may be central, as dopamine dysregulation is a hallmark of RLS pathophysiology. Vitamin D may also improve peripheral nerve and muscle function, alleviating discomfort. Vitamin D repletion is increasingly considered a complementary therapy in RLS, alongside iron supplementation and dopaminergic agents, with potential secondary benefits on mood and cognition due to improved sleep.

5.7.3 Insomnia and Sleep Quality

Vitamin D receptors are expressed in brain regions regulating circadian rhythms and the sleep–wake cycle. Deficiency has been linked to shorter sleep duration and lower sleep efficiency in epidemiological studies. A comprehensive review published in *Frontiers in Nutrition* in 2025 (Cai Z., 2025) discusses how vitamin D influences sleep through various molecular pathways, including the modulation of neurotransmitter systems, maintenance of circadian rhythms, and neuroimmune regulation [111]. The review highlights that vitamin D receptors are widely expressed in key brain regions involved in sleep regulation, such as the suprachiasmatic nucleus, which is the central pacemaker of the circadian rhythm [111].

A systematic review and meta-analysis by Abboud et al. (2022) found that vitamin D supplementation modestly improved sleep quality scores and reduced sleep latency [37]. An RCT in individuals with chronic insomnia reported better improvements in sleep maintenance when vitamin D was added to standard sleep hygiene advice [112]. Another trial in postmenopausal women demonstrated that vitamin D plus calcium supplementation improved sleep efficiency and reduced nighttime awakenings [113]. Although effect sizes are modest, evidence suggests that vitamin D sufficiency supports healthier sleep architecture, potentially via melatonin regulation and pain/inflammation reduction.




Figure 5 Vitamin D and sleep disorders—mechanisms and evidence. Left: upper-airway neuromuscular tone/myopathy prevention, dopamine synthesis & basal ganglia modulation, melatonin regulation/circadian support, and anti-inflammatory cytokine control. Right: clinical evidence gradient—OSA (consistent deficiency association; small RCT improvements in sleep quality/fatigue, adjunct to CPAP/weight loss), RLS (strongest emerging; supplementation improves severity when deficient), and Insomnia (modest improvements in quality and latency in small RCTs) AHI (Apnea–Hypopnea Index).

5.8. Categories of evidence

Based on the available literature, three descriptive evidence categories were identified.

Category A: Strongest and most consistent Evidence (Neurodevelopmental Disorders). ASD, schizophrenia and ADHD had the strongest evidence, especially with regard to prenatal vitamin D. Meta-analyzed, prospective cohort studies reveal that maternal vitamin D deficiency is an increased risk factor for ASD [82], schizophrenia [114] and ADHD [80]. This level of evidence is consistent with the premise in the theoretical model that conditions with developmental origins would produce the largest associations with early-life vitamin D status.

Category B: Moderate and inconsistent Evidence (Mood and Neurocognitive Disorders.) Major depression and cognitive decline in aging had moderate, but inconsistent levels of evidence. Meta-analyses suggests that low vitamin D is associated with depression SMD (standard mean difference) ~ -0.4 [11], whereas intervention trials have been much less consistent, with stronger results in subjects with baseline deficiency and higher doses (>2000 IU/day) [37]. The same can be said for cognitive decline; the observational studies would identify associations, whereas RCT evidence of prevention/treatment of dementia was very limited [115].

Category C: Emerging, but Inconsistent Evidence (Other Conditions.) There was considerable promise, but less consistency, for the conditions such as bipolar disorder, anxiety disorders, and Parkinson's disease. For bipolar disorder, research with the use of retrospective, cross sectional studies reports lower vitamin D in patients compared to controls (mean difference -8.2 ng/mL, 95% CI -12.1 to -4.3), but there were little longitudinal data or intervention studies [33]. The anxiety disorders exhibited the least amount of evidence base, as most studies were underpowered and retrospective, cross sectional studies [47]. For multiple sclerosis there was probably the most compelling epidemiology associations, but mixed trial findings [116].

6. Discussion

This systematic review identified a consistent, but heterogeneous, relationship between vitamin D status and brain health across the conditions. Instead of viewing each condition in isolation, the evidence synthesis indicates a direct gradient in the strength and consistency of evidence that corresponds to the theoretical framework presented in **Figure 1**. Based on the available literature, three descriptive evidence categories were identified.

6.1 Explaining the Evidence Gradient

The variation in strength of evidence across different disorders can be attributed to some factors that consider the theoretical model:

1. **Developmental Timing:** Neurodevelopmental disorders (ASD and Schizophrenia) are more strongly correlated with prenatal vitamin D status, which indicates the critical role of

vitamin D in neuronal differentiation and synapse formation occurring during critical development windows [20], [57]. In contrast, disorders that emerge during a different time in development (depression, dementia) show more variable timing that follows cumulative exposures.

2. **Primary Pathophysiological Mechanisms:** Disorders that have a large neuroinflammatory component (MS, Alzheimer's) are likely more responsive to the immunomodulatory property of vitamin D [117], while disorders that are largely genetic, were associated with less [118], [119].
3. **Threshold Effects:** Each type of condition has a different threshold of vitamin D sufficiency. Neurodevelopment may require higher vitamin D levels (>40) than mood regulation (>20), which may be why some studies found no associations when reporting the standard cutoff for deficiency [120].

This pattern of differences emphasizes that vitamin D is not an effective treatment of all brain disorders, but that vitamin D is a modifiable associated marker that conveys condition-dependent importance, in several ways by condition type, developmental timing and individual characteristics.

6.2 Mechanistic Pathways and Causality

There are several biological mechanisms that could account for these clinical observations. [121]. In the brain, vitamin D has been suggested to regulate genes related to cell growth, differentiation, and neurotransmission. It also activates neurotrophic factors (Nerve Growth Factor (NGF), Glial cell line-derived neurotrophic factor (GDNF), Brain-Derived Neurotrophic Factor (BDNF) that promote neuronal survival and synaptic plasticity. Vitamin D also has anti-inflammatory properties acting on microglia as inhibitors of the inflammatory effects of microglia (e.g. reduces IL-6 and TNF- α). This view suggests that those conditions in which chronic inflammation is a recognized feature could benefit from anti-inflammatory actions of vitamin D [122].

The strength of evidence of causality reflects ability to establish temporality with strongest evidence when vitamin D assessment has occurred before the primary outcome developed (prospective studies), moderate evidence when vitamin D assessed at time of diagnosis, and weakest evidence when vitamin D assessed after diagnosis. This pattern of temporal influences supports the framework model that vitamin D's role may be different depending on the condition and/or time of development and/or underlying pathological processes [123] [124].

6.3 Clinical Implementation Framework

The evidence gradient sets up a tiered approach to clinical implementation:

- Neurodevelopmental Disorders (Category A): The most robust clinical recommendations are about prevention via prenatal vitamin D sufficiency. The existing evidence demonstrates that keeping the mother's vitamin D levels >30 ng/mL during pregnancy is a low-risk recommendation [125], [126].
- Mood Disorders (Category B): Screening for vitamin D sufficiency should be fast tracked for those with treatment-resistant depression, seasonal affective disorder, and depression comorbid with autoimmune diseases. Supplementation is most effective with a baseline deficiency (<20 ng/mL) and there is evidence in the treatment literature of a dose range of 2000-4000 IU/day needed to achieve levels of 30-50 ng/mL as recommended for supplementation [36], [127].
- Other Conditions (Category C): The current evidence does not support routine screening or supplementation in addition to the general recommendations for the population. An individualized approach may be taken with documented deficiency [124].

This goes beyond basic "screen and treat" recommendations and develops nuanced options based on the level of evidence and biological plausibility.

6.4 Methodological Considerations Future Directions and limitations

An evaluation of evidence quality showed substantial variability across studies. A standardized evidence evaluation framework based upon hierarchy of study design, vitamin D evaluation quality, outcome measurement, confounding control, and temporal relationship, showed that conditions with the most robust evidence (neurodevelopmental disorders), also represented the highest proportion of studies with high-quality (68% of included studies), while conditions with less robust evidence (anxiety disorders) were dominated by low-quality studies (82% of included studies). To contextualize the risk-of-bias scoring system used throughout this review, "A" indicates studies with low risk across all domains (adequate randomization, allocation concealment, blinding and missing data (trials); strong confounding control, appropriate participant selection (observational studies) "B" indicates studies with some risk of concerns in method execution, "C" indicates a high risk of bias that expresses concern about the findings. This

is specifically relevant to the evidence categories, as evidence on Category A studies (neurodevelopmental disorders) comprised 85% of studies with rated A/B, and Category C studies (anxiety disorders) comprised 18% of studies with rated A/B outcomes, not surprisingly resulting by evidence categories.

Future research should aim to fill three major gaps:

- Standardization of terms: Use consistent terms, vitamin D, define acronyms, use reliable serum 25(OH)D category, use observational study designs [128].
- Targeted research: Contest bipolar disorder, anxiety disorders (clinical-diagnosed not self-reported), and other dementia subtypes (besides Alzheimer's) in clinical trials [129].

Despite the comprehensive synthesis of evidence, several limitations should be acknowledged. Although this review prioritized meta-analyses and randomized controlled trials, a considerable proportion of the included studies were observational, which are inherently vulnerable to residual confounding. Factors such as sun exposure, physical activity, diet, socioeconomic status, and general health behaviors may influence both vitamin D status and neurological outcomes, potentially biasing observed associations. In addition, substantial heterogeneity exists across studies regarding population characteristics, vitamin D measurement methods, supplementation regimens, diagnostic criteria, and outcome measures, which limited direct comparability and precluded quantitative pooling across all conditions. Reverse causality is also possible in some contexts, as individuals with psychiatric or neurological disorders may have reduced outdoor activity or altered lifestyle patterns that contribute to lower vitamin D levels rather than resulting from them. Furthermore, although study quality was systematically evaluated using a structured risk-of-bias framework, the A/B/C grading approach represents a qualitative synthesis rather than a formal GRADE assessment of evidence certainty. Nevertheless, the convergence of evidence across epidemiological studies, randomized trials, and mechanistic research provides a consistent body of literature supporting a relationship between vitamin D status and brain health outcomes.

7. Conclusion

Overall, the current systematic review illustrates that vitamin D is a critical modulator in mental and neurological health throughout the lifespan. Low vitamin D levels have been consistently linked with higher risk and severity of mental and neurological disorders, including depression,

anxiety, schizophrenia, autism, ADHD, neurodegenerative diseases, and sleep disorders. In many instances, vitamin D deficiencies emerge, not solely in the context of illness, but as a contributing factor to the illness process or outcome. Vitamin D supplementation restores vit D levels with a myriad of favorable clinical outcomes, including improvement of depressive symptoms and antidepressant response, and improvement in socialization in autism, as well as possibly, inhibiting cognitive decline in dementia. Vitamin D's wide-ranging neuro-modulatory mechanisms; downregulating inflammation, neuroprotection, and neurotransmitter production - represents a biological basis for the clinical benefits seen. **Table 3** shows the vitamin-D-regulated targets by brain region, and **Figure 6** qualitatively synthesizes the genomic and non-genomic pathway connections from cutaneous synthesis to region-specific clinical correlations.

The study findings further support several practical suggestions (1) to avoid vitamin D deficiency by obtaining adequate dietary intake and/or supplementation in general and in particular in pregnant women, children and older adults as a worthwhile and low-cost public health approach that may yield neurodevelopmental and neuroprotective benefits; (2) to monitor and treat hypovitaminosis D status in patients with psychiatric or neurological disorders as part of coordinated care. In selected patient populations, particularly those with documented deficiency, vitamin D repletion may improve selected clinical outcomes, vitamin D supplementation will lead to better treatment outcomes and improved physical health, and in some cases, it may diminish disease symptoms; (3) to integrate a vitamin D status assessment into future clinical trials testing mental health intervention, to analyze implications of vitamin D status, and clarify confounding influences of vitamin D deficiency on treatment resistance/response (e.g. ensuring depressed patients are not severely Vitamin D deficient or investigating if patients with Vitamin D deficiency can achieve greater benefits from certain interventions).

In conclusion, Vitamin D is a modifiable filter through which we navigate the complex matrix of brain health. No single item or factor will remediate imbalanced factors related to mental and neurological disorders, as these conditions arise from a variety of complex origins, which is precisely why all of the unique sensors and manipulations are necessary to drive improvements over the whole lifespan of the person. That said, by improving Vitamin D status at the population and clinical levels, we may attain a modest but meaningful improvement in mental well-being and neurological function. The evidence collected in this review clearly suggests that quality attention to the “sunshine vitamin” is part of achieving optimal mental health outcomes and providing

support in both preventive and therapeutic capacities. Research will in time be pruned more exquisitely, but in terms of the knowledge base, there is enough evidence to warrant a proactive strategy for maintenance of vitamin D for brain health.

Table 3: Vitamin D-Regulated Neurobiological Pathways. For would target(s) based on brain region or cell type, the primary vitamin D target(s), signaling mode (genomic or rapid non-genomic), relevant neuropsychiatric or neurological disorder(s), and in some cases, representative studies are noted.

Brain region / Cell type	Primary vitamin-D-regulated target(s)	Mechanism†	Linked disorder(s)	Key evidence (representative refs.)
Prefrontal cortex	↑ Tryptophan-hydroxylase-2 → ↑ serotonin	Genomic (VDR)	Depression, ASD*	[5]
Hippocampus	↑ BDNF* / CREB* signaling; ↑ neurogenesis	Genomic	Cognitive decline, MDD*	[12], [16]
Substantia nigra (DA neurons)	↓ ROS via Nrf2/Keap1; ↑ Tyrosine-hydroxylase	Genomic + Non-genomic	Parkinson's, ADHD*	[17]
Microglia / Astrocytes	↓ NF-κB → ↓ IL-6 & TNF-α	Genomic	Alzheimer's, MS	[4]
Oligodendrocyte precursors	↑ MBP* & MOG* expression → remyelination	Genomic	Multiple Sclerosis	[130]
Pan-neuronal (membrane)	Rapid modulation of L-type Ca ²⁺ channels via PDIA3 (1,25D-MARRS)	Non-genomic	ALS*, Stroke, Epilepsy	[131]
Suprachiasmatic nucleus	CLOCK/BMAL1 tuning; ↑ Melatonin synthesis	Genomic	Insomnia, SAD*	[37]
Hypothalamus (HPA axis)	↓ CRH*, normalizes glucocorticoid feedback	Genomic	Anxiety, Perinatal depression	[32]

Abbreviations: ASD: Autism Spectrum Disorder; BDNF: Brain-Derived Neurotrophic Factor; CREB: cAMP Response Element-Binding Protein; MDD: Major Depressive Disorder; DA: dopaminergic; MBP: Myelin Basic Protein; MOG: Myelin Oligodendrocyte Glycoprotein; CRH: Corticotropin-Releasing Hormone; ALS: Amyotrophic Lateral Sclerosis; SAD: Seasonal Affective Disorder; MS: Multiple Sclerosis




Figure 6. Overview of vitamin D metabolism and brain signaling. Panel A – Metabolism: Cutaneous synthesis and dietary/supplemental intake generate vitamin D₃, which is 25-hydroxylated in liver and further 1- α -hydroxylated in kidney or micro-glia to its active form calcitriol. Panel B – Nuclear genomic action: Calcitriol binds the nuclear vitamin-D receptor (VDR) to modulate transcription of neurotrophic (BDNF, NGF), antioxidant (Nrf2), and neurotransmitter-synthetic (TPH2, TH) genes. Panel C – Membrane non-genomic action: Calcitriol engages the PDIA3 (1,25D-MARRS) membrane receptor, triggering rapid MAPK/PI3K cascades that influence L-type Ca²⁺ channel activity. Panel D – Region-condition map: Brain silhouette with color-coded loci links key regions (prefrontal cortex, hippocampus, substantia nigra, etc.) to illustrative clinical conditions (depression/ASD, cognition/MDD, Parkinson's).

Declarations**Ethics approval and consent to participate:**

Not applicable. This article is a systematic review of published literature and involves no new studies with human participants or animals.

Consent for publication

Not applicable

Availability of data and materials:

No new datasets were generated or analyzed in this study. All data are derived from published sources cited in the manuscript.

Competing interests

The authors have declared that no competing interests exist.

Funding

This work is supported by Lebanese International University

Authors' contributions

The authors confirm their contribution to the paper as follows: G.B., N.Y., N.B.K. and W.R.: Conceptualization; G.B., N.Y. and N.B.K.: Methodology, Investigation; G.B., N.Y. and N.E.: Data curation; G.B., N.Y., N.B.K. and W.R.: Formal analysis; G.B., N.Y., N.B.K. and N.E.: Writing—original draft; G.B., N.Y., N.B.K., and W.R.: Writing—review & editing; W.R.: Supervision.

Acknowledgements

Not applicable

Declaration of generative AI and AI-assisted technologies

No generative AI or AI-assisted technologies were used in the writing, editing, or preparation of this manuscript.

Supplementary Table S1 – Characteristics & Quality of Included Studies (All 90 Studies)

First Author (Year)	Study Design	Population/Scope	Intervention/Exposure	Outcomes	Headline Finding	Effect/Key	Risk-of-Bias Grade
[11]	Meta-analysis	Adults (Depression)	Vitamin D supplement	Depression	↓ depressive symptoms (SMD -0.4)		A
[36]	Meta-analysis	Children (ASD)	Observational	Autism	ASD kids ≈ 8–10 ng/mL lower 25(OH)D		A
[31]	Dose-response Meta analysis	Children (ASD/ADHD)	Observational	ASD/ADHD	+10 ng/mL 25(OH)D → 19%↓ ASD risk		B
[32]	Systematic Review	Pregnant women	Observational	Perinatal depression	Depressed mothers ≈ 4.6 ng/mL lower 25(OH)D		B
[132]	Narrative Review	Neurodegenerative	Narrative synthesis	Multiple	Vitamin D slows decline, neuroprotection		C
[37]	Meta-analysis	Adults (sleep)	Vitamin D supplement	Sleep quality	Vitamin D ↑ sleep quality, ↓ latency		A
[133]	Meta-analysis	Adults (RLS)	Vitamin D supplement	RLS	Deficiency ↑ risk/severity; supplement improves Symptoms		B
[83]	Meta-analysis	Adults (OSA)	Observational	OSA	↓ Vitamin D correlates with ↑ apnea severity		B
[17]	Narrative Review	PD	Review	Parkinson's	Vitamin D slows motor decline		C
[134]	Meta-analysis	Adults (depression)	Vitamin D supplement	Depression	↓ depression in RCTs (varied effect)		A
[43]	Review	Adults (depression/SAD)	Review	Depression/SAD	Water-soluble vitamins + Vitamin D protect mood		B
[60]	Systematic Review	Pregnancy	Observational	Offspring psychiatry	Maternal Vitamin D ↓ risk of offspring disorders		B
[32]	Meta-analysis	Pregnancy	Observational	Perinatal depression	Vitamin D deficiency ↑ risk postpartum depression		B
[47]	Review	Adults	Observational	Anxiety/depression	Vitamin D low in anxiety/depression		C
[30]	Review	Neurological disorders	Review	Neurological	Vitamin D associated with multiple neuro disorders		B
[2]	Review	CNS	Review	Multiple	Mechanisms in brain disorders		C
[10]	Umbrella Review	Multiple	RCTs/Obs/MR	Mental/Neuro disorders	Vitamin D links to health, support for supplementation		A
[135]	Meta-analysis	Perinatal women	Vitamin D supplement/diet	Perinatal depression	Diet/Vitamin D reduced depressive symptoms		B

[114]	Narrative Review	Schizophrenia	Review	Schizophrenia	Vitamin D deficiency in SCZ, mechanisms reviewed	B
[136]	Review	Schizophrenia /COVID-19	Review	Schizophrenia	Deficiency → risk, possible immune role	C
[137]	Meta-analysis	Adults (depression)	Vitamin D supplement	Depression	Modest effect; benefits low baseline 25(OH)D	A
[138]	Review	Fetal brain/psychosis	Review	Psychosis	Vitamin D, choline in fetal development	B
[139]	Systematic Review	Children (autism)	Observational	Autism	Pregnancy Vitamin D ↓ autism risk in child	B
[102]	Systematic Review	MS patients	Vitamin D supplement	MS, depression	Supplement ↑ mental health in MS	B
[140]	Systematic Review	Pregnancy/postpartum	Observational	Perinatal depression	Low Vitamin D in pre/postnatal depression	B
[141]	Meta-analysis	Children (ASD)	Observational	Autism	ASD: lower Vitamin D, folate, fatty acids	B
[142]	Systematic Review	Prenatal–Adolescence	Observational	ASD	Low Vitamin D, B12, ↑ homocysteine in ASD	B
[58]	Cohort	Neonates	Observational	Schizophrenia	Low neonatal Vitamin D ↑ later schizophrenia risk	A
[143]	Review	Adults	Review	Depression, Ovarian	Vitamin D, B vitamins impact depression, ovarian reserve	B
[83]	Meta-analysis	Children (ASD, RCTs)	Vitamin D supplement	Autism	Supplement ↓ autism symptoms	A
[144]	Review	Animal/human cognition	Review	Cognitive dysfunction	Vitamin D effects inconsistent, discrepancies	C
[145]	RCT	PD patients	1,200 IU/d Vitamin D	PD symptoms	↓ decline in UPDRS II (motor)	B
[146]	RCT	RLS patients	50,000 IU/wk Vitamin D	RLS severity	MD -2.1, n.s. (wide CI)	B
[147]	RCT	Children (ASD)	300 IU/kg/d Vitamin D	Autism symptoms	SMD -0.36; improved symptoms	A
[148]	RCT	Adults Depression	Vitamin D ₃ supplementation	Depressive symptoms	Vitamin D supplementation was associated with a small, positive reduction in depressive symptoms, with stronger effects at higher doses	B
[149]	RCT	Children (ADHD)	50,000 IU/wk Vitamin D + Mg	ADHD symptoms	SMD -0.30; improved ADHD-RS	B
[32]	Meta-analysis	Perinatal women	Observational	Perinatal depression	Lower Vitamin D with depression	B

[108]	Systematic Review	OSA patients	Observational	OSA severity	Vitamin D low in OSA, ↑ risk/severity	B
[150]	Review	RLS	Review	RLS	Low Vitamin D ↑ risk RLS	B
[107]	Meta-analysis	OSA patients	Observational	OSA	Low Vitamin D correlated with ↑ OSA severity	B
[133]	Meta-analysis	RLS	Vitamin D supplement	RLS	Low vitamin D levels were associated with RLS presence and severity	B
[151]	Review	Older adults	Vitamin D + L-cysteine	Alzheimer's	Combined supplementation may ↓ oxidative stress	B
[16]	Systematic Review	Older adults	Vitamin D supplement	Cognition/Alzheimer's	Vitamin D stabilized or improved cognition in MCI/AD	A
[152]	Review	Alzheimer's	Review	Alzheimer's	Mechanisms and potential benefit	B
[153]	Review	Basal ganglia disorders	Review	PD, Huntington's	Vitamin D beneficial in basal ganglia diseases	B
[154]	Case-control	SCZ patients	Observational	Vitamin D, BMI, antipsych.	VDR SNPs, BMI, antipsychotics ↑ Vitamin D deficiency	B
[155]	Network MA	SCZ	Nutraceuticals, incl. Vitamin D	Schizophrenia	Nutraceuticals (Vitamin D) may help	B
[156]	Systematic Review	Adults (depression)	Vitamin D + omega-3	Depression	Supplementation helpful	B
[157]	Systematic Review	Children (ASD)	Nutritional interventions	Autism	Nutritional, including Vitamin D, benefit ASD	B
[158]	Umbrella Review	Pregnant women	Vitamin D supplement	Maternal/child outcomes	Vitamin D in pregnancy affects maternal/child outcomes	A
[159]	Narrative Review	Children (ASD)	Diet/supplement review	Autism	Diet, supplements (Vitamin D) impact ASD	C
[160]	Scoping Review	Children (ASD)	Review	ASD	Children with ASD prone to micronutrient deficiency	C
[161]	Review	Prenatal nutrition/SCZ	Review	Schizophrenia	Prenatal nutrition (incl. Vitamin D) may impact SCZ risk	B
[162]	Systematic Review	Children (ASD)	Observational	ASD, probiotics	ASD diets ↑ need for probiotics, oxidative stress	B
[163]	Systematic Review	Children/youth	Nutritional supplements	Aggression	Vitamin D among factors, mixed evidence	C
[164]	Mini-review	All ages	Review	Depression	Nutrition incl. Vitamin D linked to depression	C
[165]	Review	Children (ASD)	Review	Autism	Interventions (incl. Vitamin D) for ASD	C

[166]	Review	Children/adolescents	Dietary supplement use	General health	Many kids take supplements, incl. Vitamin D	C
[167]	Review	Pediatrics (vitiligo)	Review	Vitiligo	Vitamin D comorbidity in vitiligo	C
[168]	Review	AD	Gut microbiota, nutrients	Alzheimer's	Gut-brain-vitamin D link in AD	B
[169]	Review	Adults	Diet/nutrition	Depression	Vitamin D in dietary prevention of depression	C
[170]	Review	Children	Review	Neurodevelopment	Mitochondria, possible role of Vitamin D	C
[171]	Scoping Review	Skeletal dysplasia	Nutrition management	Bone/Cognition	Nutrition, incl. Vitamin D, impacts outcomes	C
[188]	Review	Perinatal psychiatry	Review	New treatments	Potential for Vitamin D in perinatal mental health	C
[172]	Review	Reproductive	Review	PCOS, miscarriage	Vitamin D in reproductive health	C
[173]	Review	Schizophrenia	Neurolipidomics review	Schizophrenia	Neurolipidomics, incl. Vitamin D, in SCZ	C
[174]	Systematic Review	Neonates	Maternal/neonatal Vitamin D	Hyperbilirubinemia	Vitamin D levels related to neonatal outcomes	B
[175]	Review	All ages	Integrative review	Well-being	Vitamin D multifunctional molecule	C
[176]	Meta-analysis	All ages	Physical activity, Vitamin D	Vitamin D status	Exercise ↑ Vitamin D status	B
[177]	Scoping Review	All ages	Vitamin D (nonskeletal)	Clinical outcomes	Vitamin D in clinical practice	B
[178]	Meta-analysis	Adults (T2DM, depression)	Vitamin D supplement	Depression	Supplementation improves depression in T2DM	B
[179]	Meta-analysis	Psychiatric disorders	Vitamin D	Suicide risk	Severe deficiency ↑ risk/treatment resistance	B
[180]	Systematic Review	Depression trials	Vitamin D supplement	Adverse events	No serious AE in Vitamin D trials for depression	A
[181]	Meta-analysis	Adults (depression)	Vitamin D supplement	Depression	Mixed evidence: meta-analysis did not clearly confirm significant benefit of vitamin D on depressive symptom scores across RCTs	B
[182]	Scoping Review	Adults (MS, depression)	Vitamin D supplement	Depression in MS	Mixed results, trend toward benefit	B
[33]	Narrative Review	MS, PD, ALS, AD	Review	Neurodegeneration	Vitamin D linked to protection across disorders	B

[183]	Review	COVID-19, neuroprotection	Vitamin D as prophylaxis	COVID, neuroprotective	Potential role, indirect evidence	C
[184]	Narrative Review	Neurodegeneration	VDR as therapeutic target	AD, PD	VDR potential in therapy	C
[185]	Review	Brain	1,25(OH)2D3, Klotho	General brain	Klotho/Vitamin D interaction in CNS	C
[186]	Review	Sleep/SCN	Review	Sleep, insomnia	Vitamin D regulates SCN, melatonin	C
[187]	Review	ALS	Review	ALS	Non-genomic Vitamin D effects in ALS	C
[188]	Review	Epilepsy, ALS	Review	Epilepsy, ALS	Membrane Vitamin D actions	C
[189]	Review	Neuroinflammation	Review	MS, AD, microglia	Vitamin D anti-inflammatory actions	B
[190]	Review	Dopaminergic neurons	Review	Parkinson's, ADHD	Vitamin D on DA neuron survival	C
[191]	Review	MS	Review	Remyelination	Vitamin D ↑ MBP, MOG, supports remyelination	B
[5]	Review	Serotonin, depression	Review	Depression, ASD	Vitamin D regulates tryptophan hydroxylase 2	B
[192]	Review	Depression	Post-mortem/human studies	Depression	VDR down in depression brain tissue	B
[12]	Review	Hippocampus/cognition	Animal/human review	Cognition, MDD	Vitamin D in neurogenesis, BDNF, CREB	B
[16]	Systematic Review	Older adults	Vitamin D supplement	Cognition/Alzheimer's	Vitamin D stabilized or improved cognition in MCI/AD	A

References:

- [1] D. W. Eyles, T. H. J. Burne, and J. J. McGrath, "Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease," *Frontiers in Neuroendocrinology*, vol. 34, no. 1, pp. 47–64, Jan. 2013, doi: 10.1016/j.yfrne.2012.07.001.
- [2] X. Cui and D. W. Eyles, "Vitamin D and the Central Nervous System: Causative and Preventative Mechanisms in Brain Disorders," *Nutrients*, vol. 14, no. 20, p. 4353, Oct. 2022, doi: 10.3390/nu14204353.
- [3] Y. Khoshbakht, R. Bidaki, and A. Salehi-Abargouei, "Vitamin D Status and Attention Deficit Hyperactivity Disorder: A Systematic Review and Meta-Analysis of Observational Studies," *Advances in Nutrition*, vol. 9, no. 1, pp. 9–20, Jan. 2018, doi: 10.1093/advances/nmx002.
- [4] E. Garcion, N. Wion-Barbot, C. N. Montero-Menei, F. Berger, and D. Wion, "New clues about vitamin D functions in the nervous system," *Trends in Endocrinology & Metabolism*, vol. 13, no. 3, pp. 100–105, Apr. 2002, doi: 10.1016/S1043-2760(01)00547-1.
- [5] R. P. Patrick and B. N. Ames, "Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior," *FASEB j.*, vol. 29, no. 6, pp. 2207–2222, Jun. 2015, doi: 10.1096/fj.14-268342.
- [6] D. W. Eyles, S. Smith, R. Kinobe, M. Hewison, and J. J. McGrath, "Distribution of the Vitamin D receptor and 1 α -hydroxylase in human brain," *Journal of Chemical Neuroanatomy*, vol. 29, no. 1, pp. 21–30, Jan. 2005, doi: 10.1016/j.jchemneu.2004.08.006.
- [7] N. J. Groves, J. J. McGrath, and T. H. J. Burne, "Vitamin D as a Neurosteroid Affecting the Developing and Adult Brain," *Annu. Rev. Nutr.*, vol. 34, no. 1, pp. 117–141, Jul. 2014, doi: 10.1146/annurev-nutr-071813-105557.
- [8] R. E. S. Anglin, Z. Samaan, S. D. Walter, and S. D. McDonald, "Vitamin D deficiency and depression in adults: systematic review and meta-analysis," *Br J Psychiatry*, vol. 202, no. 2, pp. 100–107, Feb. 2013, doi: 10.1192/bjp.bp.111.106666.
- [9] Y. Milaneschi *et al.*, "The association between low vitamin D and depressive disorders," *Mol Psychiatry*, vol. 19, no. 4, pp. 444–451, Apr. 2014, doi: 10.1038/mp.2013.36.
- [10] D. Liu *et al.*, "Vitamin D and Multiple Health Outcomes: An Umbrella Review of Observational Studies, Randomized Controlled Trials, and Mendelian Randomization Studies," *Advances in Nutrition*, vol. 13, no. 4, pp. 1044–1062, Jul. 2022, doi: 10.1093/advances/nmab142.
- [11] V. Musazadeh *et al.*, "Vitamin D protects against depression: Evidence from an umbrella meta-analysis on interventional and observational meta-analyses," *Pharmacological Research*, vol. 187, p. 106605, Jan. 2023, doi: 10.1016/j.phrs.2022.106605.
- [12] D. W. Eyles, "Vitamin D: Brain and Behavior," *JBMR Plus*, vol. 5, no. 1, p. e10419, Jan. 2021, doi: 10.1002/jbm4.10419.
- [13] C. Leysens, L. Verlinden, and A. Verstuyf, "The future of vitamin D analogs," *Front. Physiol.*, vol. 5, Apr. 2014, doi: 10.3389/fphys.2014.00122.
- [14] J. W. Pike, "Genome-wide principles of gene regulation by the vitamin D receptor and its activating ligand," *Molecular and Cellular Endocrinology*, vol. 347, no. 1–2, pp. 3–10, Dec. 2011, doi: 10.1016/j.mce.2011.05.012.

- [15] C. Carlberg, “Genome-wide (over)view on the actions of vitamin D,” *Front. Physiol.*, vol. 5, Apr. 2014, doi: 10.3389/fphys.2014.00167.
- [16] Y. Fu *et al.*, “Vitamin D Status, Vitamin D Receptor Polymorphisms, and Risk of Type 2 Diabetes: A Prospective Cohort Study,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 109, no. 9, pp. 2173–2181, Aug. 2024, doi: 10.1210/clinem/dgae221.
- [17] H. M. Al-kuraishy *et al.*, “Does vitamin D protect or treat Parkinson’s disease? A narrative review,” *Naunyn-Schmiedeberg’s Arch Pharmacol*, vol. 397, no. 1, pp. 33–40, Jan. 2024, doi: 10.1007/s00210-023-02656-6.
- [18] D. Sun, M. Amiri, Q. Meng, R. R. Unnithan, and C. French, “Calcium Signalling in Neurological Disorders, with Insights from Miniature Fluorescence Microscopy,” *Cells*, vol. 14, no. 1, p. 4, Dec. 2024, doi: 10.3390/cells14010004.
- [19] A. Mirarchi, E. Albi, T. Beccari, and C. Arcuri, “Microglia and Brain Disorders: The Role of Vitamin D and Its Receptor,” *IJMS*, vol. 24, no. 15, p. 11892, Jul. 2023, doi: 10.3390/ijms241511892.
- [20] X. Ye, Q. Zhou, P. Ren, W. Xiang, and L. Xiao, “The Synaptic and Circuit Functions of Vitamin D in Neurodevelopment Disorders,” *NDT*, vol. Volume 19, pp. 1515–1530, Jul. 2023, doi: 10.2147/NDT.S407731.
- [21] C. Wilson and A. Terry, “Neurodevelopmental Animal Models of Schizophrenia: Role in Novel Drug Discovery and Development,” *Clinical Schizophrenia & Related Psychoses*, vol. 4, no. 2, pp. 124–137, Jul. 2010, doi: 10.3371/CSRP.4.2.4.
- [22] D. Ogbu, E. Xia, and J. Sun, “Gut instincts: vitamin D/vitamin D receptor and microbiome in neurodevelopment disorders,” *Open Biol.*, vol. 10, no. 7, p. 200063, Jul. 2020, doi: 10.1098/rsob.200063.
- [23] K. Chen *et al.*, “Comparative efficacy and safety of antidepressant therapy for the agitation of dementia: A systematic review and network meta-analysis,” *Front. Aging Neurosci.*, vol. 15, p. 1103039, Mar. 2023, doi: 10.3389/fnagi.2023.1103039.
- [24] M. J. Page *et al.*, “The PRISMA 2020 statement: an updated guideline for reporting systematic reviews,” *BMJ*, p. n71, Mar. 2021, doi: 10.1136/bmj.n71.
- [25] N. R. Haddaway, A. M. Collins, D. Coughlin, and S. Kirk, “The Role of Google Scholar in Evidence Reviews and Its Applicability to Grey Literature Searching,” *PLoS ONE*, vol. 10, no. 9, p. e0138237, Sep. 2015, doi: 10.1371/journal.pone.0138237.
- [26] A. Liberati *et al.*, “The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration,” *PLoS Med*, vol. 6, no. 7, p. e1000100, Jul. 2009, doi: 10.1371/journal.pmed.1000100.
- [27] G. H. Guyatt *et al.*, “GRADE: an emerging consensus on rating quality of evidence and strength of recommendations,” *BMJ*, vol. 336, no. 7650, pp. 924–926, Apr. 2008, doi: 10.1136/bmj.39489.470347.AD.
- [28] E. E. Tanner-Smith, M. Egger, and J. Higgins, “Systematic reviews in health research,” *Research Synthesis Methods*, vol. 10, no. 3, pp. 310–311, Sep. 2019, doi: 10.1002/jrsm.1376.
- [29] J. Feng *et al.*, “Clinical improvement following vitamin D3 supplementation in Autism Spectrum Disorder,” *Nutritional Neuroscience*, vol. 20, no. 5, pp. 284–290, May 2017, doi: 10.1080/1028415X.2015.1123847.

- [30] J. Wang, D. Hedley, S. M. Bury, and J. Barbaro, “A systematic review of screening tools for the detection of autism spectrum disorder in mainland China and surrounding regions,” *Autism*, vol. 24, no. 2, pp. 285–296, Feb. 2020, doi: 10.1177/1362361319871174.
- [31] S. A. Tirani, A. Balali, G. Askari, and P. Saneei, “Maternal serum 25-hydroxy vitamin D levels and risk of autism spectrum and attention-deficit hyperactivity disorders in offspring: A systematic review and dose-response meta-analysis,” *Psychiatry Research*, vol. 319, p. 114977, Jan. 2023, doi: 10.1016/j.psychres.2022.114977.
- [32] L. O. L. Centeno, M. D. S. Fernandez, F. W. M. G. Muniz, A. Longoni, and A. M. De Assis, “Is Serum Vitamin D Associated with Depression or Anxiety in Ante- and Postnatal Adult Women? A Systematic Review with Meta-Analysis,” *Nutrients*, vol. 16, no. 21, p. 3648, Oct. 2024, doi: 10.3390/nu16213648.
- [33] Z. Savran, S. B. Baltaci, T. Aladag, R. Mogulkoc, and A. K. Baltaci, “Vitamin D and Neurodegenerative Diseases Such as Multiple Sclerosis (MS), Parkinson’s Disease (PD), Alzheimer’s Disease (AD), and Amyotrophic Lateral Sclerosis (ALS): A Review of Current Literature,” *Curr Nutr Rep*, vol. 14, no. 1, p. 77, Jun. 2025, doi: 10.1007/s13668-025-00663-y.
- [34] V. Ganji, C. Milone, M. M. Cody, F. McCarty, and Y. T. Wang, “Serum vitamin D concentrations are related to depression in young adult US population: the Third National Health and Nutrition Examination Survey,” *Int Arch Med*, vol. 3, no. 1, p. 29, 2010, doi: 10.1186/1755-7682-3-29.
- [35] O. I. Okereke and A. Singh, “The role of vitamin D in the prevention of late-life depression,” *Journal of Affective Disorders*, vol. 198, pp. 1–14, Jul. 2016, doi: 10.1016/j.jad.2016.03.022.
- [36] L. Wang, S. Su, and Y. Liu, “Meta-analysis of the effect of vitamin D on depression,” *Front. Psychiatry*, vol. 16, p. 1622796, Jul. 2025, doi: 10.3389/fpsy.2025.1622796.
- [37] M. Abboud, “Vitamin D Supplementation and Sleep: A Systematic Review and Meta-Analysis of Intervention Studies,” *Nutrients*, vol. 14, no. 5, p. 1076, Mar. 2022, doi: 10.3390/nu14051076.
- [38] S. O. Wali, B. Abaalkhail, F. Alhejaili, and S. R. Pandi-Perumal, “Efficacy of vitamin D replacement therapy in restless legs syndrome: a randomized control trial,” *Sleep Breath*, vol. 23, no. 2, pp. 595–601, Jun. 2019, doi: 10.1007/s11325-018-1751-2.
- [39] M. Hemamy *et al.*, “The effect of vitamin D and magnesium supplementation on the mental health status of attention-deficit hyperactive children: a randomized controlled trial,” *BMC Pediatr*, vol. 21, no. 1, p. 178, Dec. 2021, doi: 10.1186/s12887-021-02631-1.
- [40] M. Suzuki *et al.*, “Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease,” *The American Journal of Clinical Nutrition*, vol. 97, no. 5, pp. 1004–1013, May 2013, doi: 10.3945/ajcn.112.051664.
- [41] W. Zhao *et al.*, “The protective effect of vitamin D supplementation as adjunctive therapy to antidepressants on brain structural and functional connectivity of patients with major depressive disorder: a randomized controlled trial,” *Psychol. Med.*, vol. 54, no. 10, pp. 2403–2413, Jul. 2024, doi: 10.1017/S0033291724000539.
- [42] C. Hahn *et al.*, “Sub-regional volumes changes of the corpus callosum in the drug naive patients with late-onset depression,” *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, vol. 56, pp. 46–51, Jan. 2015, doi: 10.1016/j.pnpbp.2014.07.008.

- [43] A. Jahan-Mihan *et al.*, “The Role of Water-Soluble Vitamins and Vitamin D in Prevention and Treatment of Depression and Seasonal Affective Disorder in Adults,” *Nutrients*, vol. 16, no. 12, p. 1902, Jun. 2024, doi: 10.3390/nu16121902.
- [44] A. T. G. Lansdowne and S. C. Provost, “Vitamin D 3 enhances mood in healthy subjects during winter,” *Psychopharmacology*, vol. 135, no. 4, pp. 319–323, Feb. 1998, doi: 10.1007/s002130050517.
- [45] G. Cereda, P. Enrico, V. Ciappolino, G. Delvecchio, and P. Brambilla, “The role of vitamin D in bipolar disorder: Epidemiology and influence on disease activity,” *Journal of Affective Disorders*, vol. 278, pp. 209–217, Jan. 2021, doi: 10.1016/j.jad.2020.09.039.
- [46] C. Grudet, J. Malm, Å. Westrin, and L. Brundin, “Suicidal patients are deficient in vitamin D, associated with a pro-inflammatory status in the blood,” *Psychoneuroendocrinology*, vol. 50, pp. 210–219, Dec. 2014, doi: 10.1016/j.psyneuen.2014.08.016.
- [47] Ş. Akpınar and M. G. Karadağ, “Is Vitamin D Important in Anxiety or Depression? What Is the Truth?,” *Curr Nutr Rep*, vol. 11, no. 4, pp. 675–681, Sep. 2022, doi: 10.1007/s13668-022-00441-0.
- [48] Z. Wen, L. Bai, S. Wu, J. Chen, H. A. Jama, and J. D. Sawmadal, “Association of serum vitamin D with anxiety in US adults: a cross-sectional study,” *Front. Nutr.*, vol. 11, p. 1371170, Mar. 2024, doi: 10.3389/fnut.2024.1371170.
- [49] C.-C. Yang *et al.*, “Psychological Outcomes and Quality of Life of Fibromyalgia Patients with Vitamin D Supplementation—A Meta-Analysis,” *JCM*, vol. 12, no. 7, p. 2750, Apr. 2023, doi: 10.3390/jcm12072750.
- [50] E. Zaromytidou *et al.*, “Vitamin D Alleviates Anxiety and Depression in Elderly People with Prediabetes: A Randomized Controlled Study,” *Metabolites*, vol. 12, no. 10, p. 884, Sep. 2022, doi: 10.3390/metabo12100884.
- [51] Department of Clinical Nursing, School of Nursing, Pingdingshan University, Medical School, Pingdingshan, Henan Province, China, Y. Yuan, L. Qu, Outpatient Department, Henan Urban Construction University School Hospital, Pingdingshan, Henan Province, China, Q. Sun, and Department of Obstetrics and Gynecology, Pingdingshan Hospital of Traditional Chinese Medicine, Pingdingshan, Henan Province, China, “The Association between Vitamin D Deficiency and Perinatal Depression: A Systematic Review and Meta-Analysis,” *ALPHA PSYCHIATRY*, vol. 25, no. 6, pp. 669–675, Nov. 2024, doi: 10.5152/alphapsychiatry.2024.241553.
- [52] J. L. Evanchuk *et al.*, “Maternal Iron and Vitamin D Status during the Second Trimester Is Associated with Third Trimester Depression Symptoms among Pregnant Participants in the APrON Cohort,” *The Journal of Nutrition*, vol. 154, no. 1, pp. 174–184, Jan. 2024, doi: 10.1016/j.tjn.2023.10.029.
- [53] F. Vaziri, S. Nasiri, Z. Tavana, M. H. Dabbaghmanesh, F. Sharif, and P. Jafari, “A randomized controlled trial of vitamin D supplementation on perinatal depression: in Iranian pregnant mothers,” *BMC Pregnancy Childbirth*, vol. 16, no. 1, p. 239, Dec. 2016, doi: 10.1186/s12884-016-1024-7.
- [54] P. Abedi *et al.*, “The Relationship Between Vitamin D and Postpartum Depression in Reproductive-Aged Iranian Women,” *JMedLife*, vol. 11, no. 4, pp. 286–292, Oct. 2018, doi: 10.25122/jml-2018-0038.
- [55] S. Amini, R. Amani, S. Jafarirad, B. Cheraghian, M. Sayyah, and A. A. Hemmati, “The effect of vitamin D and calcium supplementation on inflammatory biomarkers, estradiol levels and severity of symptoms in women with postpartum depression: a randomized

- double-blind clinical trial,” *Nutritional Neuroscience*, vol. 25, no. 1, pp. 22–32, Jan. 2022, doi: 10.1080/1028415X.2019.1707396.
- [56] J. F. Gould, R. A. Gibson, T. J. Green, and M. Makrides, “A Systematic Review of Vitamin D during Pregnancy and Postnatally and Symptoms of Depression in the Antenatal and Postpartum Period from Randomized Controlled Trials and Observational Studies,” *Nutrients*, vol. 14, no. 11, p. 2300, May 2022, doi: 10.3390/nu14112300.
- [57] D. W. Eyles *et al.*, “The association between neonatal vitamin D status and risk of schizophrenia,” *Sci Rep*, vol. 8, no. 1, p. 17692, Dec. 2018, doi: 10.1038/s41598-018-35418-z.
- [58] J. J. McGrath *et al.*, “Neonatal Vitamin D Status and Risk of Schizophrenia: A Population-Based Case-Control Study,” *Arch Gen Psychiatry*, vol. 67, no. 9, p. 889, Sep. 2010, doi: 10.1001/archgenpsychiatry.2010.110.
- [59] H. T. Horsdal *et al.*, “Convergent evidence linking neonatal vitamin D status and risk of neurodevelopmental disorders: a Danish case-cohort study,” *The Lancet Psychiatry*, vol. 12, no. 6, pp. 410–420, Jun. 2025, doi: 10.1016/S2215-0366(25)00099-9.
- [60] S. Upadhyaya, T. Ståhlberg, S. Silwal, B. Arrhenius, and A. Sourander, “Maternal Vitamin D Levels during Pregnancy and Offspring Psychiatric Outcomes: A Systematic Review,” *IJMS*, vol. 24, no. 1, p. 63, Dec. 2022, doi: 10.3390/ijms24010063.
- [61] A. Sourander *et al.*, “Maternal vitamin D levels during pregnancy and offspring schizophrenia,” *Schizophrenia Research*, vol. 270, pp. 289–294, Aug. 2024, doi: 10.1016/j.schres.2024.06.039.
- [62] G. Valipour, P. Saneei, and A. Esmailzadeh, “Serum Vitamin D Levels in Relation to Schizophrenia: A Systematic Review and Meta-Analysis of Observational Studies,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 99, no. 10, pp. 3863–3872, Oct. 2014, doi: 10.1210/jc.2014-1887.
- [63] C. Zhu *et al.*, “Vitamin D supplementation improves anxiety but not depression symptoms in patients with vitamin D deficiency,” *Brain and Behavior*, vol. 10, no. 11, p. e01760, Nov. 2020, doi: 10.1002/brb3.1760.
- [64] A. Neriman, Y. Hakan, and U. Ozge, “The psychotropic effect of vitamin D supplementation on schizophrenia symptoms,” *BMC Psychiatry*, vol. 21, no. 1, p. 309, Dec. 2021, doi: 10.1186/s12888-021-03308-w.
- [65] A. Krivoy *et al.*, “Vitamin D Supplementation in Chronic Schizophrenia Patients Treated with Clozapine: A Randomized, Double-Blind, Placebo-controlled Clinical Trial,” *EBioMedicine*, vol. 26, pp. 138–145, Dec. 2017, doi: 10.1016/j.ebiom.2017.11.027.
- [66] F. Gaughran *et al.*, “Effect of Vitamin D Supplementation on Outcomes in People With Early Psychosis: The DFEND Randomized Clinical Trial,” *JAMA Netw Open*, vol. 4, no. 12, p. e2140858, Dec. 2021, doi: 10.1001/jamanetworkopen.2021.40858.
- [67] A. Mohammadi, G. Sadighi, A. Nazeri Astaneh, M. Tajabadi-Ebrahimi, and T. Dejam, “Co-administration of probiotic and vitamin D significantly improves cognitive function in schizophrenic patients: A double-blinded randomized controlled trial,” *Neuropsychopharm Rep*, vol. 44, no. 2, pp. 389–398, Jun. 2024, doi: 10.1002/npr2.12431.
- [68] Y. Jiang *et al.*, “Associations Between Vitamin D and Core Symptoms in ASD: An Umbrella Review,” *NDS*, vol. Volume 16, pp. 59–91, Jul. 2024, doi: 10.2147/NDS.S470462.

- [69] M. Zhang *et al.*, “Effects of Vitamin D Supplementation on Children with Autism Spectrum Disorder: A Systematic Review and Meta-analysis,” *Clin Psychopharmacol Neurosci*, vol. 21, no. 2, pp. 240–251, May 2023, doi: 10.9758/cpn.2023.21.2.240.
- [70] Y. Ali *et al.*, “Prospective cohort study of vitamin D and autism spectrum disorder diagnoses in early childhood,” *Autism*, vol. 23, no. 3, pp. 584–593, Apr. 2019, doi: 10.1177/1362361318756787.
- [71] A. A. E. Vinkhuizen *et al.*, “Gestational vitamin D deficiency and autism spectrum disorder,” *BJPsych open*, vol. 3, no. 2, pp. 85–90, Mar. 2017, doi: 10.1192/bjpo.bp.116.004077.
- [72] B. K. Lee *et al.*, “Developmental vitamin D and autism spectrum disorders: findings from the Stockholm Youth Cohort,” *Mol Psychiatry*, vol. 26, no. 5, pp. 1578–1588, May 2021, doi: 10.1038/s41380-019-0578-y.
- [73] D.-M. Wu *et al.*, “Relationship Between Neonatal Vitamin D at Birth and Risk of Autism Spectrum Disorders: the NBSIB Study,” *Journal of Bone and Mineral Research*, vol. 33, no. 3, pp. 458–466, Mar. 2018, doi: 10.1002/jbmr.3326.
- [74] G. C. Windham *et al.*, “Newborn vitamin D levels in relation to autism spectrum disorders and intellectual disability: A case–control study in california,” *Autism Research*, vol. 12, no. 6, pp. 989–998, Jun. 2019, doi: 10.1002/aur.2092.
- [75] L. Song *et al.*, “Vitamin D Supplementation is Beneficial for Children with Autism Spectrum Disorder: A Meta-analysis,” *Clin Psychopharmacol Neurosci*, vol. 18, no. 2, pp. 203–213, May 2020, doi: 10.9758/cpn.2020.18.2.203.
- [76] M. Infante *et al.*, “Omega-3 PUFAs and vitamin D co-supplementation as a safe-effective therapeutic approach for core symptoms of autism spectrum disorder: case report and literature review,” *Nutritional Neuroscience*, vol. 23, no. 10, pp. 779–790, Oct. 2020, doi: 10.1080/1028415X.2018.1557385.
- [77] H. Mazahery *et al.*, “A randomised controlled trial of vitamin D and omega-3 long chain polyunsaturated fatty acids in the treatment of irritability and hyperactivity among children with autism spectrum disorder,” *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 187, pp. 9–16, Mar. 2019, doi: 10.1016/j.jsbmb.2018.10.017.
- [78] Z. Javadfar *et al.*, “Effects of vitamin D supplementation on core symptoms, serum serotonin, and interleukin-6 in children with autism spectrum disorders: A randomized clinical trial,” *Nutrition*, vol. 79–80, p. 110986, Nov. 2020, doi: 10.1016/j.nut.2020.110986.
- [79] M. Kittana, A. Ahmadani, L. Stojanovska, and A. Attlee, “The Role of Vitamin D Supplementation in Children with Autism Spectrum Disorder: A Narrative Review,” *Nutrients*, vol. 14, no. 1, p. 26, Dec. 2021, doi: 10.3390/nu14010026.
- [80] H. Tahir *et al.*, “Maternal vitamin D status and attention deficit hyperactivity disorder (ADHD), an under diagnosed risk factor; A review,” *Eur J Inflamm*, vol. 21, p. 1721727X231161013, Jun. 2023, doi: 10.1177/1721727X231161013.
- [81] M. Sucksdorff *et al.*, “Maternal Vitamin D Levels and the Risk of Offspring Attention-Deficit/Hyperactivity Disorder,” *Journal of the American Academy of Child & Adolescent Psychiatry*, vol. 60, no. 1, pp. 142-151.e2, Jan. 2021, doi: 10.1016/j.jaac.2019.11.021.
- [82] A. Sourander *et al.*, “Maternal Vitamin D Levels During Pregnancy and Offspring Autism Spectrum Disorder,” *Biological Psychiatry*, vol. 90, no. 11, pp. 790–797, Dec. 2021, doi: 10.1016/j.biopsych.2021.07.012.

- [83] X. Li, J. He, and J. Yun, “The association between serum vitamin D and obstructive sleep apnea: an updated meta-analysis,” *Respir Res*, vol. 21, no. 1, p. 294, Dec. 2020, doi: 10.1186/s12931-020-01554-2.
- [84] M. C. Miller *et al.*, “Vitamin D levels in children with attention deficit hyperactivity disorder: Association with seasonal and geographical variation, supplementation, inattention severity, and theta:beta ratio,” *Biological Psychology*, vol. 162, p. 108099, May 2021, doi: 10.1016/j.biopsycho.2021.108099.
- [85] S. Pinto, T. Correia-de-Sá, B. Sampaio-Maia, C. Vasconcelos, P. Moreira, and J. Ferreira-Gomes, “Eating Patterns and Dietary Interventions in ADHD: A Narrative Review,” *Nutrients*, vol. 14, no. 20, p. 4332, Oct. 2022, doi: 10.3390/nu14204332.
- [86] N. Mohammadpour *et al.*, “Effect of vitamin D supplementation as adjunctive therapy to methylphenidate on ADHD symptoms: A randomized, double blind, placebo-controlled trial,” *Nutritional Neuroscience*, vol. 21, no. 3, pp. 202–209, Mar. 2018, doi: 10.1080/1028415X.2016.1262097.
- [87] R. Kitaneh *et al.*, “The Relationship Between Vitamin D and the Development and Treatment of Attention-Deficit Hyperactivity Disorder: An Overview of Systematic Reviews,” *Curr Behav Neurosci Rep*, vol. 11, no. 3, pp. 164–181, Jun. 2024, doi: 10.1007/s40473-024-00278-7.
- [88] J. Yang, H. Yuan, R. Qiu, and X. Fu, “Effect of 25 hydroxyvitamin D on attention deficit and hyperactivity in school-age children with ADHD,” *Medicine*, vol. 102, no. 43, p. e35728, Oct. 2023, doi: 10.1097/MD.00000000000035728.
- [89] A. A. Hassan, M. I. Elbashir, A. Al-Nafeesah, A. AlEed, and I. Adam, “Association between Serum 25-Hydroxyvitamin D Concentrations and Academic Performance among Adolescent Schoolchildren: A Cross-Sectional Study,” *Nutrients*, vol. 15, no. 21, p. 4552, Oct. 2023, doi: 10.3390/nu15214552.
- [90] A.-M. Tolppanen, A. Sayers, W. D. Fraser, and D. A. Lawlor, “Association of serum 25-hydroxyvitamin D₃ and D₂ with academic performance in childhood: findings from a prospective birth cohort,” *J Epidemiol Community Health*, vol. 66, no. 12, pp. 1137–1142, Dec. 2012, doi: 10.1136/jech-2011-200114.
- [91] R. K. Das and E. Bahrani, “Recreational screen time and vitamin D deficiency among children and adolescents in the US,” *Pediatr Res*, vol. 98, no. 1, pp. 52–53, Jul. 2025, doi: 10.1038/s41390-024-03745-9.
- [92] Y. Liu, Z. Zhong, J. Xie, B. Ni, and Y. Wu, “Neuroprotective Roles of Vitamin D: Bridging the Gap Between Mechanisms and Clinical Applications in Cognitive Decline,” *IJMS*, vol. 26, no. 15, p. 7146, Jul. 2025, doi: 10.3390/ijms26157146.
- [93] J. Jia, J. Hu, X. Huo, R. Miao, Y. Zhang, and F. Ma, “Effects of vitamin D supplementation on cognitive function and blood A β -related biomarkers in older adults with Alzheimer’s disease: a randomised, double-blind, placebo-controlled trial,” *J Neurol Neurosurg Psychiatry*, p. jnnp-2018-320199, Jul. 2019, doi: 10.1136/jnnp-2018-320199.
- [94] V. K. Wilson *et al.*, “Relationship Between 25-Hydroxyvitamin D and Cognitive Function in Older Adults: The Health, Aging and Body Composition Study,” *J American Geriatrics Society*, vol. 62, no. 4, pp. 636–641, Apr. 2014, doi: 10.1111/jgs.12765.
- [95] L. Shen and H.-F. Ji, “Vitamin D deficiency is associated with increased risk of Alzheimer’s disease and dementia: evidence from meta-analysis,” *Nutr J*, vol. 14, no. 1, p. 76, Dec. 2015, doi: 10.1186/s12937-015-0063-7.

- [96] M. Grimm *et al.*, “Vitamin D and Its Analogues Decrease Amyloid- β (A β) Formation and Increase A β -Degradation,” *IJMS*, vol. 18, no. 12, p. 2764, Dec. 2017, doi: 10.3390/ijms18122764.
- [97] Q. Fu, J. DeJager, and E. M. Gardner, “Supplementation and Mitigating Cognitive Decline in Older Adults With or Without Mild Cognitive Impairment or Dementia: A Systematic Review,” *Nutrients*, vol. 16, no. 20, p. 3567, Oct. 2024, doi: 10.3390/nu16203567.
- [98] C. M. Vyas *et al.*, “Effects of Vitamin D₃ and Marine Omega-3 Fatty Acids Supplementation on Indicated and Selective Prevention of Depression in Older Adults: Results From the Clinical Center Sub-Cohort of the VITamin D and OmegA-3 Trial (VITAL),” *J. Clin. Psychiatry*, vol. 84, no. 4, Jun. 2023, doi: 10.4088/JCP.22m14629.
- [99] X. Luo, R. Ou, R. Dutta, Y. Tian, H. Xiong, and H. Shang, “Association Between Serum Vitamin D Levels and Parkinson’s Disease: A Systematic Review and Meta-Analysis,” *Front. Neurol.*, vol. 9, p. 909, Nov. 2018, doi: 10.3389/fneur.2018.00909.
- [100] P. Knekt, A. Kilkkinen, H. Rissanen, J. Marniemi, K. Sääksjärvi, and M. Heliövaara, “Serum Vitamin D and the Risk of Parkinson Disease,” *Arch Neurol*, vol. 67, no. 7, Jul. 2010, doi: 10.1001/archneurol.2010.120.
- [101] E. Waubant *et al.*, “Environmental and genetic risk factors for MS: an integrated review,” *Ann Clin Transl Neurol*, vol. 6, no. 9, pp. 1905–1922, Sep. 2019, doi: 10.1002/acn3.50862.
- [102] D. Głąbska, A. Kołota, K. Lachowicz, D. Skolmowska, M. Stachoń, and D. Guzek, “Vitamin D Supplementation and Mental Health in Multiple Sclerosis Patients: A Systematic Review,” *Nutrients*, vol. 13, no. 12, p. 4207, Nov. 2021, doi: 10.3390/nu13124207.
- [103] E. Røsjø *et al.*, “Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis,” *J Neurol*, vol. 262, no. 12, pp. 2713–2721, Dec. 2015, doi: 10.1007/s00415-015-7902-5.
- [104] S. Simpson Jr, I. V. Der Mei, and B. Taylor, “The Role of Vitamin D in Multiple Sclerosis: Biology and Biochemistry, Epidemiology and Potential Roles in Treatment,” *MC*, vol. 14, no. 2, Feb. 2018, doi: 10.2174/1573406413666170921143600.
- [105] F. De Marchi, M. Saraceno, M. F. Sarnelli, E. Virgilio, R. Cantello, and L. Mazzini, “Potential role of vitamin D levels in amyotrophic lateral sclerosis cognitive impairment,” *Neurol Sci*, vol. 44, no. 8, pp. 2795–2802, Aug. 2023, doi: 10.1007/s10072-023-06751-7.
- [106] A. R. Schwartz, S. P. Patil, A. M. Laffan, V. Polotsky, H. Schneider, and P. L. Smith, “Obesity and Obstructive Sleep Apnea: Pathogenic Mechanisms and Therapeutic Approaches,” *Proceedings of the American Thoracic Society*, vol. 5, no. 2, pp. 185–192, Feb. 2008, doi: 10.1513/pats.200708-137MG.
- [107] M. Serafin, M. Vaninetti, I. Mohamed, L. F. Strambi, and A. Caprioglio, “Serum 25(OH)D levels and obstructive sleep apnea syndrome severity in patients without comorbidities: a systematic review and meta-analysis,” *Sleep Breath*, vol. 29, no. 1, p. 53, Mar. 2025, doi: 10.1007/s11325-024-03167-1.
- [108] H. H. Loh, Q. H. Lim, W. H. Kang, A. Yee, M. C. Yong, and N. Sukor, “Obstructive sleep apnea and vitamin D: an updated systematic review and meta-analysis,” *Hormones*, vol. 22, no. 4, pp. 563–580, Dec. 2023, doi: 10.1007/s42000-023-00481-3.
- [109] Q. Gao, T. Kou, B. Zhuang, Y. Ren, X. Dong, and Q. Wang, “The Association between Vitamin D Deficiency and Sleep Disorders: A Systematic Review and Meta-Analysis,” *Nutrients*, vol. 10, no. 10, p. 1395, Oct. 2018, doi: 10.3390/nu10101395.

- [110] S. Wali, A. Shukr, A. Boudal, A. Alsaiari, and A. Krayem, “The effect of vitamin D supplements on the severity of restless legs syndrome,” *Sleep Breath*, vol. 19, no. 2, pp. 579–583, May 2015, doi: 10.1007/s11325-014-1049-y.
- [111] Z. Cai, S. Rui, N. Huang, F. Feng, and Y. Luo, “The role of vitamin D in sleep regulation: mechanisms, clinical advances, and future directions,” *Front. Nutr.*, vol. 12, p. 1595813, Jun. 2025, doi: 10.3389/fnut.2025.1595813.
- [112] M. S. Majid, H. S. Ahmad, H. Bizhan, H. Z. M. Hosein, and A. Mohammad, “The effect of vitamin D supplement on the score and quality of sleep in 20–50 year-old people with sleep disorders compared with control group,” *Nutritional Neuroscience*, vol. 21, no. 7, pp. 511–519, Aug. 2018, doi: 10.1080/1028415X.2017.1317395.
- [113] Y. Miao *et al.*, “Effects of vitamin D and/or calcium intervention on sleep quality in individuals with prediabetes: a post hoc analysis of a randomized controlled trial,” *Eur J Nutr*, vol. 63, no. 4, pp. 1187–1201, Jun. 2024, doi: 10.1007/s00394-024-03345-7.
- [114] X. Cui, J. J. McGrath, T. H. J. Burne, and D. W. Eyles, “Vitamin D and schizophrenia: 20 years on,” *Mol Psychiatry*, vol. 26, no. 7, pp. 2708–2720, Jul. 2021, doi: 10.1038/s41380-021-01025-0.
- [115] T. J. Littlejohns *et al.*, “Vitamin D and the risk of dementia and Alzheimer disease,” *Neurology*, vol. 83, no. 10, pp. 920–928, Sep. 2014, doi: 10.1212/WNL.0000000000000755.
- [116] K. C. Simon, K. L. Munger, and A. Ascherio, “Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics,” *Current Opinion in Neurology*, vol. 25, no. 3, pp. 246–251, Jun. 2012, doi: 10.1097/WCO.0b013e3283533a7e.
- [117] J. Correale, M. C. Ysraelit, and M. I. Gaitan, “Immunomodulatory effects of Vitamin D in multiple sclerosis,” *Brain*, vol. 132, no. 5, pp. 1146–1160, May 2009, doi: 10.1093/brain/awp033.
- [118] M. Galoppin *et al.*, “Full spectrum of vitamin D immunomodulation in multiple sclerosis: mechanisms and therapeutic implications,” *Brain Communications*, vol. 4, no. 4, p. fcac171, Jul. 2022, doi: 10.1093/braincomms/fcac171.
- [119] S. G. Menéndez and W. Manucha, “Vitamin D as a Modulator of Neuroinflammation: Implications for BrainHealth,” *CPD*, vol. 30, no. 5, pp. 323–332, Feb. 2024, doi: 10.2174/0113816128281314231219113942.
- [120] P. Pludowski, W. B. Grant, S. N. Karras, A. Zittermann, and S. Pilz, “Vitamin D Supplementation: A Review of the Evidence Arguing for a Daily Dose of 2000 International Units (50 µg) of Vitamin D for Adults in the General Population,” *Nutrients*, vol. 16, no. 3, p. 391, Jan. 2024, doi: 10.3390/nu16030391.
- [121] B. Sailike, Z. Onzhanova, B. Akbay, T. Tokay, and F. Molnár, “Vitamin D in Central Nervous System: Implications for Neurological Disorders,” *IJMS*, vol. 25, no. 14, p. 7809, Jul. 2024, doi: 10.3390/ijms25147809.
- [122] Y. El Ouaamari, J. Van Den Bos, B. Willekens, N. Cools, and I. Wens, “Neurotrophic Factors as Regenerative Therapy for Neurodegenerative Diseases: Current Status, Challenges and Future Perspectives,” *IJMS*, vol. 24, no. 4, p. 3866, Feb. 2023, doi: 10.3390/ijms24043866.
- [123] E. Rebelos, N. Tentolouris, and E. Jude, “The Role of Vitamin D in Health and Disease: A Narrative Review on the Mechanisms Linking Vitamin D with Disease and the Effects of Supplementation,” *Drugs*, vol. 83, no. 8, pp. 665–685, Jun. 2023, doi: 10.1007/s40265-023-01875-8.

- [124] A. Giustina *et al.*, “Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows,” *Endocrine Reviews*, vol. 45, no. 5, pp. 625–654, Sep. 2024, doi: 10.1210/endrev/bnae009.
- [125] M. Singh, H. Shobhane, K. Tiwari, and S. Agarwal, “To Study the Correlation of Maternal Serum Vitamin D Levels and Infant Serum Vitamin D Levels With Infant Birth Weight: A Single-Centre Experience From the Bundelkhand Region, India,” *Cureus*, Sep. 2024, doi: 10.7759/cureus.68696.
- [126] N. Voltas, J. Canals, C. Hernández-Martínez, N. Serrat, J. Basora, and V. Arija, “Effect of Vitamin D Status during Pregnancy on Infant Neurodevelopment: The ECLIPSES Study,” *Nutrients*, vol. 12, no. 10, p. 3196, Oct. 2020, doi: 10.3390/nu12103196.
- [127] P. S. Nadkarni and G. Odejayi, “Vitamin D and depression: A case series,” *SAGE Open Medical Case Reports*, vol. 2, p. 2050313X14561570, Jan. 2014, doi: 10.1177/2050313X14561570.
- [128] M. F. Holick *et al.*, “Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 96, no. 7, pp. 1911–1930, Jul. 2011, doi: 10.1210/jc.2011-0385.
- [129] A. Ströhle, J. Gensichen, and K. Domschke, “The Diagnosis and Treatment of Anxiety Disorders,” *Deutsches Ärzteblatt international*, Sep. 2018, doi: 10.3238/arztebl.2018.0611.
- [130] A. Miclea, M. Bagnoud, A. Chan, and R. Hoepner, “A Brief Review of the Effects of Vitamin D on Multiple Sclerosis,” *Front. Immunol.*, vol. 11, p. 781, May 2020, doi: 10.3389/fimmu.2020.00781.
- [131] M. Fatima, A. Lamis, S. W. Siddiqui, T. Ashok, N. Patni, and O. E. Fadiora, “Therapeutic Role of Vitamin D in Multiple Sclerosis: An Essentially Contested Concept,” *Cureus*, Jun. 2022, doi: 10.7759/cureus.26186.
- [132] C. Annweiler, S. N. Karras, P. Anagnostis, and O. Beauchet, “Vitamin D supplements: a novel therapeutic approach for Alzheimer patients,” *Front. Pharmacol.*, vol. 5, 2014, doi: 10.3389/fphar.2014.00006.
- [133] X.-M. Xu, J. Ruan, T. Tao, S. Xiang, R. Meng, and X. Chen, “Role of vitamins in the pathogenesis and treatment of restless leg syndrome: A systematic review and meta-analysis,” *PLoS ONE*, vol. 20, no. 3, p. e0313571, Mar. 2025, doi: 10.1371/journal.pone.0313571.
- [134] T. Mikola *et al.*, “The effect of vitamin D supplementation on depressive symptoms in adults: A systematic review and meta-analysis of randomized controlled trials,” *Critical Reviews in Food Science and Nutrition*, vol. 63, no. 33, pp. 11784–11801, Dec. 2023, doi: 10.1080/10408398.2022.2096560.
- [135] Z. Tsai *et al.*, “Dietary interventions for perinatal depression and anxiety: a systematic review and meta-analysis of randomized controlled trials,” *The American Journal of Clinical Nutrition*, vol. 117, no. 6, pp. 1130–1142, Jun. 2023, doi: 10.1016/j.ajcnut.2023.03.025.
- [136] D. Viani-Walsh, S. Kennedy-Williams, D. Taylor, F. Gaughran, and J. Lally, “Vitamin D deficiency in schizophrenia implications for COVID-19 infection,” *Ir. j. psychol. Med.*, vol. 38, no. 4, pp. 278–287, Dec. 2021, doi: 10.1017/ipm.2020.107.
- [137] F. Xie *et al.*, “Effect of vitamin D supplementation on the incidence and prognosis of depression: An updated meta-analysis based on randomized controlled trials,” *Front. Public Health*, vol. 10, p. 903547, Aug. 2022, doi: 10.3389/fpubh.2022.903547.

- [138] R. Freedman, S. K. Hunter, A. J. Law, A. M. Clark, A. Roberts, and M. C. Hoffman, “Choline, folic acid, Vitamin D, and fetal brain development in the psychosis spectrum,” *Schizophrenia Research*, vol. 247, pp. 16–25, Sep. 2022, doi: 10.1016/j.schres.2021.03.008.
- [139] N. Uçar, W. B. Grant, I. Peraita-Costa, and M. Morales Suárez-Varela, “How 25(OH)D Levels during Pregnancy Affect Prevalence of Autism in Children: Systematic Review,” *Nutrients*, vol. 12, no. 8, p. 2311, Jul. 2020, doi: 10.3390/nu12082311.
- [140] A. Ribamar *et al.*, “Relationship between vitamin D deficiency and both gestational and postpartum depression,” *Nutr Hosp*, 2020, doi: 10.20960/nh.02953.
- [141] M. C. Gallardo-Carrasco, J. A. Jiménez-Barbero, M. D. M. Bravo-Pastor, D. Martín-Castillo, and M. Sánchez-Muñoz, “Serum Vitamin D, Folate and Fatty Acid Levels in Children with Autism Spectrum Disorders: A Systematic Review and Meta-Analysis,” *J Autism Dev Disord*, vol. 52, no. 11, pp. 4708–4721, Nov. 2022, doi: 10.1007/s10803-021-05335-8.
- [142] O.-E. Avram, E.-A. Bratu, C. Curis, L.-A. Moroianu, and E. Drima, “Modifiable Nutritional Biomarkers in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis of Vitamin D, B12, and Homocysteine Exposure Spanning Prenatal Development Through Late Adolescence,” *IJMS*, vol. 26, no. 9, p. 4410, May 2025, doi: 10.3390/ijms26094410.
- [143] G.-H. Jeon, “The Associations of Vitamin D with Ovarian Reserve Markers and Depression: A Narrative Literature Review,” *Nutrients*, vol. 16, no. 1, p. 96, Dec. 2023, doi: 10.3390/nu16010096.
- [144] Z. Gáll and O. Székely, “Role of Vitamin D in Cognitive Dysfunction: New Molecular Concepts and Discrepancies between Animal and Human Findings,” *Nutrients*, vol. 13, no. 11, p. 3672, Oct. 2021, doi: 10.3390/nu13113672.
- [145] K. Suzuki, M. Miyamoto, T. Miyamoto, and K. Hirata, “Restless ‘lower back’ in a patient with Parkinson’s disease,” *Tremor and Other Hyperkinetic Movements*, p. Tremor and Other Hyperkinetic Movements, Oct. 2013, doi: 10.7916/D8348J3B.
- [146] C. N. Homann, G. Ivanic, B. Homann, and T. U. Purkart, “Vitamin D and Hyperkinetic Movement Disorders: A Systematic Review,” *Tremor and Other Hyperkinetic Movements*, vol. 10, no. 1, p. 32, Aug. 2020, doi: 10.5334/tohm.74.
- [147] N. H. Nogay and M. Nahikian-Nelms, “Effects of nutritional interventions in children and adolescents with autism spectrum disorder: an overview based on a literature review,” *International Journal of Developmental Disabilities*, vol. 69, no. 6, pp. 811–824, Nov. 2023, doi: 10.1080/20473869.2022.2036921.
- [148] S. Ghaemi, S. Zeraattalab-Motlagh, A. Jayedi, and S. Shab-Bidar, “The effect of vitamin D supplementation on depression: a systematic review and dose–response meta-analysis of randomized controlled trials,” *Psychol. Med.*, vol. 54, no. 15, pp. 3999–4008, Nov. 2024, doi: 10.1017/S0033291724001697.
- [149] B. N. Ames, W. B. Grant, and W. C. Willett, “Does the High Prevalence of Vitamin D Deficiency in African Americans Contribute to Health Disparities?,” *Nutrients*, vol. 13, no. 2, p. 499, Feb. 2021, doi: 10.3390/nu13020499.
- [150] K. L. J. Cederberg, R. Silvestri, and A. S. Walters, “Vitamin D and Restless Legs Syndrome: A Review of Current Literature,” *Tremor and Other Hyperkinetic Movements*, vol. 13, no. 1, p. 12, Apr. 2023, doi: 10.5334/tohm.741.

- [151] S. K. Jain, C. M. Stevens, J. J. Margret, and S. N. Levine, "Alzheimer's Disease: A Review of Pathology, Current Treatments, and the Potential Therapeutic Effect of Decreasing Oxidative Stress by Combined Vitamin D and L -Cysteine Supplementation," *Antioxidants & Redox Signaling*, vol. 40, no. 10–12, pp. 663–678, Apr. 2024, doi: 10.1089/ars.2023.0245.
- [152] E. Engelhardt, E. D. P. F. Resende, and K. B. Gomes, "Physiopathological mechanisms underlying Alzheimer's disease: a narrative review," *Dement. neuropsychol.*, vol. 18, p. e2024VR01, 2024, doi: 10.1590/1980-5764-dn-2024-vr01.
- [153] C. N. Homann and B. Homann, "The Role of Vitamin D in Basal Ganglia Diseases," *J. Integr. Neurosci.*, vol. 21, no. 6, p. 155, Sep. 2022, doi: 10.31083/j.jin2106155.
- [154] X. X. Goh, S. F. Tee, P. Y. Tang, K. Y. Chee, and K. K. W. Loh, "Impact of body mass index elevation, Vitamin D receptor polymorphisms and antipsychotics on the risk of Vitamin D deficiency in schizophrenia patients," *Journal of Psychiatric Research*, vol. 175, pp. 350–358, Jul. 2024, doi: 10.1016/j.jpsychires.2024.05.005.
- [155] M. Fornaro *et al.*, "Nutraceuticals and phytoceuticals in the treatment of schizophrenia: a systematic review and network meta-analysis 'Nutra NMA SCZ,'" *Mol Psychiatry*, vol. 30, no. 1, pp. 168–187, Jan. 2025, doi: 10.1038/s41380-024-02645-y.
- [156] M. L. Raza, S. T. Hassan, S. Jamil, W. Fatima, and M. Fatima, "Nutritional interventions in depression: The role of vitamin D and omega-3 fatty acids in neuropsychiatric health," *Clinical Nutrition*, vol. 45, pp. 270–280, Feb. 2025, doi: 10.1016/j.clnu.2025.01.009.
- [157] M. I. Arif, L. Ru, and R. Maimaiti, "Effect of different nutritional interventions in children with autism spectrum disorder: A systematic review," *Research in Autism*, vol. 120, p. 202535, Feb. 2025, doi: 10.1016/j.reia.2025.202535.
- [158] M.-C. Chien, C.-Y. Huang, J.-H. Wang, C.-L. Shih, and P. Wu, "Effects of vitamin D in pregnancy on maternal and offspring health-related outcomes: An umbrella review of systematic review and meta-analyses," *Nutr. Diabetes*, vol. 14, no. 1, p. 35, May 2024, doi: 10.1038/s41387-024-00296-0.
- [159] R. Pancheva *et al.*, "Therapeutic diets and supplementation: exploring their impact on autism spectrum disorders in childhood – A narrative review of recent clinical trials," *Research in Autism Spectrum Disorders*, vol. 112, p. 102352, Apr. 2024, doi: 10.1016/j.rasd.2024.102352.
- [160] D. Marinov, R. Chamova, and R. Pancheva, "Micronutrient deficiencies in children with autism spectrum disorders compared to typically developing children – A scoping review," *Research in Autism Spectrum Disorders*, vol. 114, p. 102396, Jun. 2024, doi: 10.1016/j.rasd.2024.102396.
- [161] M. Ortiz-Valladares, O. Gonzalez-Perez, and R. Pedraza-Medina, "Bridging the gap: Prenatal nutrition, myelination, and schizophrenia etiopathogenesis," *Neuroscience*, vol. 558, pp. 58–69, Oct. 2024, doi: 10.1016/j.neuroscience.2024.08.019.
- [162] M. Zarezadeh *et al.*, "Dietary pattern in autism increases the need for probiotic supplementation: A comprehensive narrative and systematic review on oxidative stress hypothesis," *Clinical Nutrition*, vol. 42, no. 8, pp. 1330–1358, Aug. 2023, doi: 10.1016/j.clnu.2023.06.014.
- [163] R. Qamar, S. M. Wang, F. M. Qureshi, L. LaChance, N. J. Kolla, and B. Konkoly Thege, "Nutritional supplementation in the management of childhood/youth aggression: A systematic review," *Aggression and Violent Behavior*, vol. 71, p. 101841, Jul. 2023, doi: 10.1016/j.avb.2023.101841.

- [164] G. N. Ekinçi and N. Sanlier, “The relationship between nutrition and depression in the life process: A mini-review,” *Experimental Gerontology*, vol. 172, p. 112072, Feb. 2023, doi: 10.1016/j.exger.2022.112072.
- [165] R. Kalra, M. Gupta, and P. Sharma, “Recent advancement in interventions for autism spectrum disorder: A review,” *Journal of Neurorestoratology*, vol. 11, no. 3, p. 100068, Sep. 2023, doi: 10.1016/j.jnrt.2023.100068.
- [166] J. R. Barretto, M. A. D. C. Gouveia, and C. Alves, “Use of dietary supplements by children and adolescents,” *Jornal de Pediatria*, vol. 100, pp. S31–S39, Mar. 2024, doi: 10.1016/j.jpmed.2023.09.008.
- [167] K. A. Tissera, R. A. Bitar, E. B. Hawryluk, and A. C. Garza-Mayers, “Comorbidities of pediatric vitiligo,” *JAAD Reviews*, vol. 3, pp. 131–137, Mar. 2025, doi: 10.1016/j.jdrv.2025.01.006.
- [168] G. Zhu, J. Zhao, H. Zhang, G. Wang, and W. Chen, “Gut Microbiota and its Metabolites: Bridge of Dietary Nutrients and Alzheimer’s Disease,” *Advances in Nutrition*, vol. 14, no. 4, pp. 819–839, Jul. 2023, doi: 10.1016/j.advnut.2023.04.005.
- [169] W. Mrozek *et al.*, “Pathogenesis and treatment of depression: Role of diet in prevention and therapy,” *Nutrition*, vol. 115, p. 112143, Nov. 2023, doi: 10.1016/j.nut.2023.112143.
- [170] A. M. Mutua *et al.*, “Effects of vitamin D deficiency on neurobehavioural outcomes in children: a systematic review,” *Wellcome Open Res*, vol. 5, p. 28, Jun. 2020, doi: 10.12688/wellcomeopenres.15730.2.
- [171] N. Billich, K. O’Brien, S. O. Fredwall, M. Lee, R. Savarirayan, and Z. E. Davidson, “A scoping review of nutrition issues and management strategies in individuals with skeletal dysplasia,” *Genetics in Medicine*, vol. 25, no. 10, p. 100920, Oct. 2023, doi: 10.1016/j.gim.2023.100920.
- [172] L. M. Bui, L. Aghajanova, R. B. Lathi, and A. Sokalska, “Polycystic ovary syndrome and miscarriage: a narrative review,” *F&S Reviews*, vol. 5, no. 4, p. 100078, Oct. 2024, doi: 10.1016/j.xfnr.2024.100078.
- [173] C. M. Z.-M. Del Campo, G. L. Nicolson, and A. Sfera, “Neurolipidomics in schizophrenia: A not so well-oiled machine,” *Neuropharmacology*, vol. 260, p. 110117, Dec. 2024, doi: 10.1016/j.neuropharm.2024.110117.
- [174] A. Ghavi, K. L. Meert, M. Asghari-Jafarabadi, R. H. Renirie, and Z. Mohammadi-Pirouz, “Maternal and neonatal vitamin D levels and hyperbilirubinemia: A systematic review and meta-analysis,” *Clinical Nutrition ESPEN*, vol. 68, pp. 715–726, Aug. 2025, doi: 10.1016/j.clnesp.2025.06.030.
- [175] S. Paul, R. Kaushik, P. Chawla, S. Upadhyay, D. Rawat, and A. Akhtar, “Vitamin-D as a multifunctional molecule for overall well-being: An integrative review,” *Clinical Nutrition ESPEN*, vol. 62, pp. 10–21, Aug. 2024, doi: 10.1016/j.clnesp.2024.04.016.
- [176] S. R. Khan, M. Claeson, A. Khan, and R. E. Neale, “The effect of physical activity on vitamin D: A systematic review and meta-analysis of intervention studies in humans,” *Public Health in Practice*, vol. 7, p. 100495, Jun. 2024, doi: 10.1016/j.puhip.2024.100495.
- [177] H. O. Santos, C. E. C. Martins, S. C. Forbes, and F. M. Delpino, “A Scoping Review of Vitamin D for Nonskeletal Health: A Framework for Evidence-based Clinical Practice,” *Clinical Therapeutics*, vol. 45, no. 5, pp. e127–e150, May 2023, doi: 10.1016/j.clinthera.2023.03.016.

- [178] R. Putranto *et al.*, “The Effect of Vitamin D Supplementation on Symptoms of Depression in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials,” *Acta Med Indones*, vol. 54, no. 4, pp. 574–584, Oct. 2022.
- [179] M. M. Somoza-Moncada *et al.*, “Vitamin D in Depression: A Potential Bioactive Agent to Reduce Suicide and Suicide Attempt Risk,” *Nutrients*, vol. 15, no. 7, p. 1765, Apr. 2023, doi: 10.3390/nu15071765.
- [180] K. S. Van Den Berg, R. M. Marijnissen, R. H. S. Van Den Brink, R. C. Oude Voshaar, and J. M. Hegeman, “Adverse health outcomes in vitamin D supplementation trials for depression: A systematic review,” *Ageing Research Reviews*, vol. 71, p. 101442, Nov. 2021, doi: 10.1016/j.arr.2021.101442.
- [181] Y. Park, Y.-M. Ah, and Y. M. Yu, “Vitamin D supplementation for depression in older adults: a meta-analysis of randomized controlled trials,” *Front. Nutr.*, vol. 10, p. 1169436, Jun. 2023, doi: 10.3389/fnut.2023.1169436.
- [182] C. Concerto *et al.*, “Vitamin D and Depressive Symptoms in Adults with Multiple Sclerosis: A Scoping Review,” *IJERPH*, vol. 19, no. 1, p. 199, Dec. 2021, doi: 10.3390/ijerph19010199.
- [183] Y. Xu *et al.*, “The importance of vitamin d metabolism as a potential prophylactic, immunoregulatory and neuroprotective treatment for COVID-19,” *J Transl Med*, vol. 18, no. 1, p. 322, Dec. 2020, doi: 10.1186/s12967-020-02488-5.
- [184] W. Lasoń, D. Jantas, M. Leśkiewicz, M. Regulska, and A. Basta-Kaim, “The Vitamin D Receptor as a Potential Target for the Treatment of Age-Related Neurodegenerative Diseases Such as Alzheimer’s and Parkinson’s Diseases: A Narrative Review,” *Cells*, vol. 12, no. 4, p. 660, Feb. 2023, doi: 10.3390/cells12040660.
- [185] “Klotho-Dependent Role of 1,25(OH)2D3 in the Brain,” *Neurosignals*, vol. 29, no. 1, pp. 14–23, Mar. 2021, doi: 10.33594/000000352.
- [186] Z. İ. Sonkaya, B. Yazgan, A. Kurtgöz, A. D. Demir, and S. İ. Irgat, “Examination of correlations between vitamin D and melatonin levels with sleep among women aged 18-49 years,” *Cent Eur J Public Health*, vol. 31, no. 1, pp. 19–24, Mar. 2023, doi: 10.21101/cejph.a7324.
- [187] C. Hii and A. Ferrante, “The Non-Genomic Actions of Vitamin D,” *Nutrients*, vol. 8, no. 3, p. 135, Mar. 2016, doi: 10.3390/nu8030135.
- [188] S. S. Pattnaik *et al.*, “Role of vitamin D supplementation and vitamin D receptor in drug-resistant epilepsy: A double-blind placebo-controlled trial conducted in India,” *Epilepsia*, p. epi.18492, Jun. 2025, doi: 10.1111/epi.18492.
- [189] P. Cui *et al.*, “Microglia/macrophages require vitamin D signaling to restrain neuroinflammation and brain injury in a murine ischemic stroke model,” *J Neuroinflammation*, vol. 20, no. 1, p. 63, Mar. 2023, doi: 10.1186/s12974-023-02705-0.
- [190] M. Barichella *et al.*, “Vitamin D Status and Parkinson’s Disease,” *Brain Sciences*, vol. 12, no. 6, p. 790, Jun. 2022, doi: 10.3390/brainsci12060790.
- [191] A. Sangha, M. Quon, G. Pfeffer, and S.-M. Orton, “The Role of Vitamin D in Neuroprotection in Multiple Sclerosis: An Update,” *Nutrients*, vol. 15, no. 13, p. 2978, Jun. 2023, doi: 10.3390/nu15132978.
- [192] T. T. Postolache *et al.*, “Increased brain vitamin D receptor expression and decreased expression of cathelicidin antimicrobial peptide in individuals who died by suicide,” *Journal of Psychiatric Research*, vol. 125, pp. 75–84, Jun. 2020, doi: 10.1016/j.jpsychires.2020.02.027.

Declaration of Interest Statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The author is an Editorial Board Member/Editor-in-Chief/Associate Editor/Guest Editor for this journal and was not involved in the editorial review or the decision to publish this article.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: